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8During inﬂammation, excess production 
and release of matrix proteinases, including 
matrix metalloproteinases (MMPs) and 
serine proteinases, may result in dysregulated 
extracellular proteolysis leading to 
development of tissue damage. Injurious 
inﬂammatory pulmonary reaction may play 
an important role in the pathogenesis of 
bronchopulmonary dysplasia (BPD). The 
aims of the present study were to evaluate 
involvement of MMPs and serine proteinase 
trypsin in acute and chronic lung injury 
in preterm infants and to study the role of 
MMPs and trypsin in development of acute 
lung injury by means of an animal model of 
hyperoxic lung injury. 
Samples of tracheal aspirate ﬂuid (TAF) 
were collected during the early postnatal 
period from preterm infants with respiratory 
distress. Molecular forms of MMP-2, -8, 
and -9, and their speciﬁc inhibitor, tissue 
inhibitor of metalloproteinases (TIMP)-
2, were identiﬁed by Western blotting 
and their relative levels by densitometry. 
Concentrations of trypsinogen-1, and -2, and 
tumor-associated trypsin inhibitor (TATI) 
were measured by immunoﬂuorometry. 
Expression of trypsin-2 and proteinase-
activated receptor 2 (PAR
2
) in lung tissue 
was studied by immunohistochemistry 
performed on autopsy lung specimens 
from fetuses, from preterm infants with 
respiratory distress syndrome (RDS) or BPD, 
and from newborn infants who had died for 
nonpulmonary reasons. In the experimental 
study, rats were exposed to >95% oxygen for 
24, 48, and 60 h, or room air. Expression of 
trypsin, MMP-2, MMP-8, and MMP-9 was 
studied in samples of bronchoalveolar lavage 
ﬂuid (BALF) by zymography and Western 
blotting. Immunohistochemistry for trypsin 
and MMP-8 was performed on pulmonary 
samples.
Higher MMP-8 and lower TIMP-2 
appeared in TAF from preterm infants with 
more severe acute respiratory distress. 
ABSTRACT
9Preterm infants subsequently developing BPD 
had higher MMP-8 levels during the early 
postnatal period than did those who survived 
without it. Low TIMP-2 levels during the 
early postnatal period were associated with 
poor respiratory outcome. We found that high 
pulmonary concentrations of trypsinogen-2 
early postnatally were associated with the 
severity of acute lung injury and subsequent 
development of BPD. Immunohistochemistry 
revealed the expression of trypsin-2 in 
bronchial epithelium; in preterm infants 
with prolonged RDS, also in alveolar 
epithelium. Since trypsin-2 is potent 
activator of PAR
2
, a G-protein coupled 
receptor involved in inﬂammation, we next 
studied the expression of PAR
2
 in the lung. 
We observed that PAR
2
 co-localized with 
trypsin-2 in bronchoalveolar epithelium, and 
a higher level of PAR
2
 immunoreactivity was 
detectable in bronchoalveolar epithelium of 
preterm infants with prolonged RDS than 
in newborn infants without lung disorders. 
In experimental animals, a rapid increase in 
BALF levels of trypsin and MMP-8 appeared 
early in the course of hyperoxic lung injury. 
By immunohistochemistry, strong expression 
of trypsin was detectable in alveolar 
epithelium, and MMP-8 was predominantly 
localized in macrophages at 48 and 60 hours 
of hyperoxia.
In conclusion, high levels of MMP-8 
and trypsin-2 in TAF early postnatally are 
associated with the severity of acute lung 
injury and subsequent development of BPD 
in preterm infants. In the injured preterm 
lung, trypsin-2 co-localizes with PAR
2
 in 
bronchoalveolar epithelium, suggesting that 
PAR
2
 activated by high levels of trypsin-
2 may be involved in lung inﬂammation 
associated with development of BPD. The 
marked increase in pulmonary expression 
of MMP-8 and trypsin early in the course 
of experimental hyperoxic lung injury 
suggests that these enzymes play a role in the 
development of acute lung injury. 
10
1. LUNG INJURY 
1.1. Normal lung development
The normal development of the human lung 
can be divided into the following 5 stages 
(reviewed in Bland and Coalson 2000): 1) 
Embryonic stage (0 to 7 weeks), development 
of airways to the level of bronchopulmonary 
segments; 2) Pseudoglandular stage (5 to 17 
weeks), a phase characterized by branching 
of the airway and arterial tree down to the 
preacinar level; 3) Canalicular stage (16 to 
26 weeks), a phase when prospective gas-
exchanging tissue is formed as the peripheral 
cuboidal cells start to differentiate into type 
I and type II cells, and primitive interstitium 
is canalized by multiplication of capillaries; 
4) Saccular stage (24 to 36 weeks), during 
which peripheral airspaces expand at the 
expense of the intervening interstitium, and 
secondary crests containing a double capillary 
layer start to grow into the airspace from the 
saccular walls, a process called septation; and 
5) Alveolar stage (from week 36 to 2 years 
postnatally), the time of alveolarization, 
characterized by extension and thinning of 
the secondary crests and fusion of capillaries 
into a single medial layer to form alveoli 
(Figure 1). The process of alveolar formation, 
especially septation, is a critical phase of 
lung development coordinated by multiple 
interactions between epithelial and interstitial 
cells, microvascular lung components, and 
extracellular matrix (ECM) (Roth-Kleiner 
and Post 2005).  
 
1.2. Lung injury in the preterm infant 
Within the ﬁrst hours of life preterm infants 
are at risk of developing respiratory distress 
syndrome (RDS) which is primarily due to 
deﬁciency of the surfactant system resulting 
in failure of airspace expansion (Northway 
2000). In preterm infants, RDS is the most 
common cause of acute lung injury and 
respiratory failure, and these infants often 
need ventilatory support and treatment with 
supplemental oxygen. Bronchopulmonary 
dysplasia (BPD) is a chronic lung disease 
that develops in preterm infants exposed to 
multiple injurious factors including baro- 
and volutrauma, oxygen toxicity, pulmonary 
inﬂammatory response, and perinatal 
infection (Jobe and Bancalari 2001, Speer 
2003). 
When BPD was ﬁrst described in 1967 by 
Northway et al., the infants of 31 to 34 weeks 
of gestation had severe RDS, and were treated 
with prolonged mechanical ventilation and 
high inspired oxygen concentrations. With 
the advent of antenatal glucocorticoids and 
postnatal surfactant therapy, risk for severe 
RDS has decreased, and development of BPD 
is now infrequent in infants of more than 1200 
g birth weight or with gestations exceeding 
32 wk (Lemons et al. 2001, Bancalari et 
al. 2003). Concurrently, the survival rate 
of smaller and more immature infants has 
markedly increased, and BPD continues to be 
a major cause of mortality and morbidity in 
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very low birth weight (VLBW; birth weight 
≤1500 g), and especially extremely low birth 
weight (ELBW; ≤1000 g) infants born at <28 
weeks of gestation (Stevenson et al. 1998, 
Lemons et al. 2001). 
With the change in clinical presentation 
of BPD, the criteria deﬁning BPD have been 
revised. The most widely used deﬁnitions in 
the literature are the need for supplemental 
oxygen at the postnatal age of 28 days with 
radiographic changes (Bancalari et al. 1979), 
and the deﬁnition by Shennan et al. in 1988. 
The latter suggested that the requirement 
of supplemental oxygen at 36 gestational 
weeks with characteristic radiographic 
changes was a better predictor of abnormal 
pulmonary outcome in VLBW infants with 
gestational ages of 30 weeks or less (Shennan 
et al. 1988). Using the 36 weeks´ deﬁnition, 
approximately 44% of the surviving ELBW 
infants nowadays develop BPD (Ehrenkranz 
et al. 2005). In 2000, a severity-based 
consensus deﬁnition of BPD was suggested 
with differing criteria for infants born at 
gestational ages of greater or less than 32 
weeks (Jobe and Bancalari 2001). 
Figure 1. Human lung in the (A) pseudoglandular (fetus, gestational age 14 weeks), (B) canalicular (fetus, 
gestational age 21 weeks), (C) saccular (newborn, gestational age 26 weeks, age at death 2 hours), and 
(D) alveolar stage (newborn, gestational age 40 weeks, age at death 1 day). Arrows indicate secondary 
crests; as, airspace; br, bronchiole.
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1.2.1 Pathology of RDS and BPD
In lungs of preterm infants who have died of 
RDS, the autopsy shows atelectasis, hyaline 
membranes in the terminal airways and 
airspaces, and necrosis and desquamation 
of alveolar and bronchiolar epithelial cells, 
as well as alveolar and interstitial edema 
(reviewed by Coalson 2000). 
In preterm infants with RDS, BPD appears 
to proceed as a continuous process from acute 
lung injury of the ﬁrst few postnatal days 
through proliferative and reparative phases 
to chronic disease (Cherukupalli et al. 1996). 
The proliferative and reparative phases occur 
during the ﬁrst 2 weeks following acute lung 
injury, and are characterized by regeneration 
of alveolar epithelium by alveolar type II 
cells, high numbers of inﬂammatory cells 
in the airspaces, and increasing numbers of 
myoﬁbroblasts surrounding the airspaces 
(Toti et al. 1997). 
Before the use of antenatal glucocorticoids 
and postnatal surfactant, the pathology of 
fully evolved BPD was characterized by 
altered inﬂation pattern of atelectasis and 
overinﬂation, severe airway epithelial injury 
with squasmous metaplasia, hypertrophy of 
airway smooth muscle, widespread ﬁbrosis, 
and vascular hypertensive lesions (Coalson 
2000). The introduction of surfactant 
treatment and the prenatal use of antenatal 
glucocorticoids, coupled with advances in 
mechanical ventilation, have resulted in the 
new BPD pathology of the more immature 
lung showing enlarged airspaces with 
decreased alveolar and capillary development; 
whereas interstitial hypercellularity and 
ﬁbroproliferation are variable, and milder 
airway lesions are mainly detectable in 
infants with severe disease (Coalson 2003). 
1.2.2 Role of inﬂammation in lung injury in 
the preterm infant
Multiple factors are involved in the 
development of BPD, including immaturity, 
barotrauma and volutrauma, oxidative 
stress, pulmonary inﬂammation, antenatal 
and postnatal infection, and patent ductus 
arteriosus (Jobe and Bancalari 2001, Bancalari 
et al. 2003, Saugstad 2003, Speer 2003). 
Growing evidence suggests that an injurious 
inﬂammatory pulmonary reaction followed 
by dysregulated reparative processes play an 
important role in the pathogenesis of BPD 
(Speer 2003). The inﬂammatory process is 
triggered early by initial trauma caused by 
various possible factors such as resuscitation, 
initiation of mechanical ventilation, and 
oxygen toxicity. Some very small preterm 
infants, however, initially have no RDS, or 
only mild respiratory disease, but after a few 
days or weeks show progressive deterioration 
in lung function and increased ventilatory 
and oxygen requirements (Lemons et 
al. 2001, Bancalari et al. 2003). In these 
infants, the initial hits may be exposure 
to chorioamnionitis or an early postnatal 
systemic or pulmonary infection, or both 
(Watterberg et al. 1996, Jobe 2003).  
The inﬂammatory pulmonary reaction 
is characterized by early accumulation of 
inﬂammatory cells, production of multiple 
cytokines and chemokines, increased 
expression of adhesion molecules on 
endothelial and epithelial cells, secretion of 
proteinases and toxic oxygen radicals, and 
increased microvascular permeability (Speer 
2003). 
Within the ﬁrst few days of life, 
neutrophils and macrophages accumulate in 
the lungs of preterm infants with RDS, and 
greater numbers of these cells have been 
demonstrated in airway aspirates from infants 
who subsequently develop BPD than from 
those who survive without it (Merritt et al. 
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1983, Ogden et al. 1984, Groneck et al. 1994, 
Murch et al. 1996). In preterm infants who 
recover from RDS, the neutrophil counts in 
airway aspirates decline rapidly to normal by 
the end of the ﬁrst week, whereas in those 
who develop BPD, the number of neutrophils 
and macrophages remains elevated for weeks 
(Ogden et al. 1984, Groneck et al. 1994, 
Murch et al. 1996). 
In lung lavage ﬂuids from preterm 
infants developing BPD increased levels 
of chemotactic factors such as interleukin 
(IL)-8, anaphylatoxin C5a, and macrophage 
inﬂammatory protein (MIP)-1α, as well as 
proinﬂammatory cytokines including IL-
1ß, tumor necrosis factor (TNF)-α, IL-6, 
are detectable during the ﬁrst and second 
postnatal weeks (Groneck et al. 1994, 
Kotecha et al. 1996, Murch et al. 1996). 
During this inﬂammatory process, 
production and release of potent proteinases 
by activated inﬂammatory cells and lung 
resident cells are increased, and these 
enzymes may play an important role in 
the development of tissue injury (Speer 
2003). The role of proteolytic injury in the 
development of BPD was ﬁrst suggested by 
Merritt et al., who in 1983 demonstrated in 
airway aspirates from preterm infants who 
subsequently developed BPD an imbalance 
between neutrophil elastase and its inhibitor 
α
1
-antitrypsin (also called α
1
-proteinase 
inhibitor). 
The involvement of inﬂammation in 
disrupted lung alveolarization in these 
infants is supported by ﬁndings in animal 
models of BPD (Warner et al. 1998, Coalson 
et al. 1999, Wagenaar et al. 2004). At birth, 
the murine lung is at the saccular stage of 
lung development, with alveolarization 
taking place during the ﬁrst 2 weeks of life. 
Prolonged exposure of newborn mice and 
rats to hyperoxia interferes with the process 
of septation and results in chronic lung injury 
with pathological changes similar to those 
seen in infants with BPD (Warner et al. 1998, 
Wagenaar et al. 2004). In these animals, the 
pulmonary inﬂammatory response develops 
during the ﬁrst week of exposure, and persists 
into the second week; it is characterized by 
inﬂux of neutrophils and macrophages, by 
interstitial and alveolar edema, and by induced 
synthesis of various cytokines, chemokines, 
and proteinases (Warner et al. 1998, Wagenaar 
et al. 2004). The role of inﬂammation in 
the development of BPD has also been 
evidenced in the immature baboon model of 
BPD, which is characterized by preterm birth 
at the canalicular stage of lung development, 
comparable to the 24- to 26-week human 
infant, by use of antenatal glucocortics and 
postnatal prophylactic surfactant, coupled 
with appropriate oxygenation and positive 
pressure ventilation (Coalson et al. 1999). 
1.3. Experimental hyperoxic lung injury in 
adult rat
Hyperoxia-induced lung injury (exposure 
to >95% oxygen) is a widely used model of 
acute lung injury and acute respiratory distress 
syndrome (ARDS). In the rat, hyperoxic lung 
injury is characterized by damage to the 
alveolar–capillary barrier with subsequent 
increased pulmonary vascular permeability, 
progressive inﬂammation, and pulmonary 
edema. The early stages of oxygen toxicity 
begin with an initiation phase, occurring 
within the ﬁrst 40 hours of hyperoxia exposure, 
in which are few demonstrable morphologic 
changes (Crapo et al. 1980). The ﬁrst signs of 
increased alveolar-capillary permeability are 
detected at 48 hours (Royston et al. 1990). 
Lung inﬂammation evident by inﬁltration of 
neutrophils into the lung interstitium occurs 
after 48 hours (Nishio et al. 1998). Increased 
pulmonary expression of intercellular 
adhesion molecule-1 (ICAM-1) plays an 
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important role in subsequent neutrophil 
transmigration into the airspace (Nishio et al. 
1998) where high numbers of these cells as 
well as alveolar macrophages can be detected 
after 60 hours of oxygen exposure (Barry and 
Crapo 1985, Narasaraju et al. 2003). Severe 
tissue injury resulting from direct oxidative 
cell damage by increased reactive oxygen 
species and excessive inﬂammation leads to 
interstitial and alveolar edema at 60 hours and 
eventually to death usually within 72 hours 
of exposure (Crapo et al. 1980, Royston et 
al. 1990, Pagano and Barazzone-Argiroffo 
2003). 
Figure 2. Domain structure of MMPs. The domain organization of MMPs is as indicated: S, signal peptide; 
Pro, propeptide; Cat, catalytic domain; Zn, active-site zinc; Hpx, hemopexin domain; Fn, ﬁbronectin domain; 
I, type I transmembrane domain; II, type II transmembrane domain; G, GPI anchor; Cp, cytoplasmic domain; 
V, vitronectin insert; Ca, cysteine array region; and Ig, IgG-like domain.  A furin-cleavage site is depicted as 
a black band between propeptide and catalytic domains. Modiﬁed from Visse and Nagase (2003).  
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The matrix metalloproteinases (MMPs) are a 
family of structurally and functionally related 
endopeptidases capable of degrading almost 
all components of the ECM and basement 
membranes (BM) (Birkedal-Hansen et al. 
1993). In addition to their role in destruction 
and remodeling of the ECM, MMPs are 
important regulators of the functions of 
various biologically active molecules such 
as proinﬂammatory cytokines, chemokines, 
growth factors, and serine proteinase 
inhibitors (Vu and Werb 2000, Stamenkovic 
2003, Parks et al. 2004). Thus, MMPs 
are involved in many physiological and 
pathological processes including embryonic 
development, inﬂammation, immunity, and 
cancer (Vu and Werb 2000, Stamenkovic 
2003, Parks et al. 2004). The catalytic activity 
of MMPs is controlled at several points, e.g., 
at the level of transcription, by activation 
of the secreted zymogens (proMMPs), and 
through inhibition of the active enzyme by 
several endogenous inhibitors, of which 
the tissue inhibitors of metalloproteinases 
(TIMPs) are the most important (Nagase and 
Woessner 1999).
In humans, to date, the number of MMPs 
is 23 (Nagase et al. 2006). All MMPs share 
a basic domain structure comprising 1) a 
signal peptide that targets them for secretion, 
2) a propeptide with a cysteine residue which 
ligates the catalytic zinc ion for preservation of 
latency, and 3) a catalytic domain containing 
the zinc-binding site (Birkedal-Hansen et 
al. 1993, Nagase and Woessner 1999). Most 
of the MMPs also have a hinge region and 
a carboxy-terminal hemopexin-like domain, 
both of which are lacking in MMP-7, -23, 
and -26. In addition, some domains are 
restricted to subgroups of MMPs, such 
as gelatin-binding domains present in the 
catalytic domain of the gelatinases (MMP-2 
and MMP-9). These domains contain repeats 
of ﬁbronectin motifs which facilitate enzyme 
binding to gelatin. Of the six membrane-
type MMPs (MT-MMPs), four (MMP-14, 
-15, -16, and -24) have transmembrane and 
intracellular domains, whereas two (MMP-
17 and -25) have glycosylphosphatidylinosi
tol (GPI) anchors, which target them to the 
cell surface (Nagase et al. 2006) (Figure 2).
2.1. Members of the MMP family
MMPs are divided into 6 subgroups based on 
their structural characteristics and substrate 
speciﬁcity: collagenases (MMP-1, MMP-
8, and MMP-13), gelatinases (MMP-2 and 
MMP-9), stromelysins (MMP-3, MMP-10, 
and MMP-11), matrilysins (MMP-7 and 
MMP-26), MT-MMPs (MMP-14, MMP-15, 
MMP-16, MMP-17, MMP-24, MMP-25), 
and other MMPs (MMP-12, MMP-19, MMP-
20, MMP-21, MMP-23, MMP-27, MMP-28) 
(Birkedal-Hansen et al. 1993, Nagase et al. 
2006).
2.1.1. Collagenases
MMP-1, MMP-8, and MMP-13 (collagenase-
1, -2, and -3) belong to the collagenase 
subgroup of the MMPs. A unique feature 
of these enzymes is their capacity to cleave 
native interstitial collagens I, II, and III at a 
speciﬁc site of the alpha chain. This cleavage 
results in generation of ¾ amino terminal 
and ¼ carboxy terminal fragments, which, 
at body temperature, denature rapidly into 
gelatin, and are subsequently degraded by 
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gelatinolytic MMPs. MMP-1 prefers type 
III collagen, whereas MMP-8 preferentially 
cleaves type I and II collagens, and MMP-
13 cleaves type II collagen more efﬁciently 
than other ﬁbrillar collagens (Birkedal-
Hansen et al. 1993, Knäuper et al. 1996). 
Collagenases can also cleave various other 
components of ECM, as well as nonmatrix 
proteins such as serine proteinase inhibitors, 
α
2
-macroglobulin, and certain inﬂammatory 
mediators (McQuibban et al. 2002, Balbin et 
al. 2003, Owen et al. 2004). 
MMP-1 and MMP-13 are mainly 
expressed in vivo during the active ECM 
remodeling associated with physiological 
situations such as fetal bone development and 
tissue repair, as well as various pathological 
conditions including inﬂammatory diseases 
and malignant tumors  (Inada et al. 2004, 
Ala-aho and Kähäri 2005, Pardo and Selman 
2005). 
As for MMP-8, during early differentiation 
in the bone marrow, neutrophils synthesize 
MMP-8 and store it in a latent 75 to 85-kD form 
in speciﬁc intracellular granules. This highly 
glycosylated isoform of MMP-8 is released 
in latent form from activated neutrophils 
upon degranulation (Hasty et al. 1986). A 
signiﬁcant part of the released enzyme is 
subsequently associated with the cell surface 
of neutrophils, where it is detectable in both 
latent and active form (Owen et al. 2004). 
The mesenchymal MMP-8 isoform is a less-
glycosylated 50 to 55-kD form of MMP-8, 
which is expressed by several types of cells 
such as stimulated chondrocytes, rheumatoid 
synovial ﬁbroblasts, oral carcinoma cells, and 
chorionic cells of human fetal membranes 
(Cole et al. 1996, Hanemaaijer et al. 1997, 
Moilanen et al. 2003, Arechavaleta-Velasco 
et al. 2004). 
Activation of MMP-8 by proteinases 
such as trypsin-2, chymotrypsin, cathepsin 
G, MMP-3, and MMP-14 converts the 
latent forms of neutrophil-derived MMP-8 
(Knäuper et al. 1990, Knäuper et al. 1993, 
Holopainen et al. 2003, Moilanen et al. 
2003) and mesenchymal cell-derived MMP-
8 (Moilanen et al. 2003) into active forms 
of 65 to 75-kD and 45 kD, respectively. 
MMP-8 can also be activated in vitro by 
myeloperoxidase-derived reactive oxygen 
species, and this activation mechanism does 
not necessarily involve change in molecular 
mass (Saari et al. 1990). 
In addition to its collagenolytic properties, 
MMP-8 is capable of degrading α
1
-antitrypsin 
and of processing chemokines, and it is also 
involved in the generation of apoptotic signals 
for inﬂammatory cells, suggesting that MMP-
8 may play a signiﬁcant role in the regulation 
of inﬂammation  (Balbin et al. 2003, Owen et 
al. 2004, Gueders et al. 2005). 
2.1.2. Gelatinases
MMP-2 (gelatinase A) and MMP-9 (gelatinase 
B) were originally described as gelatin-
binding proteins (Vartio and Vaheri 1981, 
Vartio et al. 1982). They degrade several 
ECM proteins such as denatured collagens 
or gelatins, type IV and type V collagens, 
elastin, ﬁbronectin, and vitronectin, as well 
as a number of non-matrix proteins including 
proteinase inhibitors, certain cytokines and 
chemokines, and latent growth factors and 
growth factor binding proteins (Björklund and 
Koivunen 2005, Chakrabarti and Patel 2005). 
Both MMP-2 and MMP-9 proteolytically 
process the inactive proforms of transforming 
growth factor-beta (TGF-β) and IL-1β into 
their corresponding active forms (Schonbeck 
et al. 1998, Yu and Stamenkovic 2000). 
MMP-9 also processes IL-8 into a truncated 
variant with increased activity, thus causing 
more effective neutrophil chemotaxis and 
activation (Opdenakker et al. 2001). In 
addition, MMP-9 degrades α
1
-antitrypsin 
and in this way protects neutrophil elastase 
activity (Liu et al. 2000).
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In general, MMP-2 is produced constitutively 
and by a variety of cell types including 
ﬁbroblasts, endothelial cells, macrophages, 
and various malignant cells (Chakrabarti and 
Patel 2005). It is secreted in a latent 72-kD 
form, and its main activation occurs on the 
cell surface and is mediated by membrane-
type MMPs (Strongin et al. 1995, Visse and 
Nagase 2003). MMP-14 (membrane-type 1 
MMP) activation of MMP-2 occurs by the 
formation of a molecular complex containing 
MMP-2, MMP-14, and TIMP-2 which 
concentrates the components on the cell 
surface. An adjacent free and active MMP-
14 subsequently cleaves proMMP-2 to the 
64-kD intermediate form. This intermediate 
form is then processed to the fully active 62-
kD form due to autoproteolytic cleavage at a 
second site (Strongin et al. 1995, Murphy et 
al. 1999).  
In contrast to MMP-2, the expression of 
MMP-9 is highly inducible by growth factors 
and proinﬂammatory cytokines in many 
cell types including alveolar macrophages, 
alveolar and bronchial epithelial cells, 
ﬁbroblasts, endothelial cells, and malignant 
cells (Atkinson and Senior 2003, Björklund 
and Koivunen 2005). Neutrophils synthesize 
MMP-9 during maturation in the bone 
marrow, and the MMP-9 is stored in latent 
form in intracellular tertiary granules before 
its release into the extracellular space after 
neutrophil activation. MMP-9 is released 
from cells as 92-kD proMMP-9, but also 
to a signiﬁcant degree in complexed forms, 
including complexes with TIMP-1, with 
itself (200-kD homodimer), and with 
neutrophil gelatinase-associated lipocalin 
(120-kD complex) (Westerlund et al. 1996, 
Opdenakker et al. 2001). Part of the secreted 
MMP-9 is consequently bound to the cell 
surface, where it is signiﬁcantly resistant 
to inhibition by TIMP-1 (Owen et al. 2003, 
Björklund and Koivunen 2005). MMP-9 can 
be proteolytically activated to a 75 to 82-kD 
active form by trypsin-2, neutrophil elastase, 
plasmin, and uPA (Ferry et al. 1997, Mazzieri 
et al. 1997, Sorsa et al. 1997, Liu et al. 2005). 
In addition, reactive oxygen species can 
activate MMP-9 (Westerlund et al. 1996). 
Moreover, the mere binding of proMMP-
9 to gelatin or type IV collagen induces its 
enzymatic activity, without removal of the 
prodomain (Bannikov et al. 2002).
2.2. Regulation of MMPs
In healthy resting adult tissues many MMPs 
are expressed at low levels or not expressed 
at all. However, several factors such as 
proinﬂammatory cytokines, growth factors, 
hormones, and cell–cell and cell–matrix 
interactions can rapidly stimulate the gene 
expression of most MMPs (Birkedal-Hansen 
et al. 1993, Nagase and Woessner 1999). 
Because neutrophil-derived MMP-8 and 
MMP-9 are not synthesized de novo by 
mature neutrophils, they are not regulated 
transcriptionally. When activated by 
proinﬂammatory mediators, degranulating 
neutrophils release the MMP-8 and MMP-
9 stored in their intracellular granules. 
The secreted enzymes are rapidly bound to 
neutrophil plasma membrane, where they 
are expressed in both pro and active forms, 
and are often colocalized on the leading edge 
of a polarized neutrophil (Owen et al. 2003, 
2004). The membrane-bound MMP-8 and 
MMP-9 have a spectrum of catalytic activity 
and a catalytic efﬁcacy similar to those 
of the soluble forms of these enzymes; in 
contrast to the soluble forms, the membrane-
bound enzymes are substantially resistant to 
inhibition by TIMP-1 and TIMP-2 (Owen 
et al. 2003, Owen et al. 2004). Cell-surface 
localization of MMP may be an important 
mechanism to maintain a high local 
enzyme concentration, and to target their 
catalytic activity to speciﬁc substrates in the 
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pericellular environment (Parks and Shapiro 
2001, Stamenkovic 2003, Parks et al. 2004).
Most of the MMPs are secreted as 
proforms, which are maintained in a 
catalytically inactive state by interaction 
between the cysteine residue of propeptide 
domain and the zinc ion of the active site. 
Disruption of this interaction is required for 
activation of proMMPs, and this can occur 
by various nonproteolytic agents such as 
organomercurials and reactive oxygen species, 
or by cleavage of the propeptide by tissue and 
plasma proteinases such as trypsin, plasmin, 
neutrophil elastase, and mast cell tryptase, 
as well as by MMPs (Birkedal-Hansen et al. 
1993, Ferry et al. 1997, Mazzieri et al. 1997, 
Sorsa et al. 1997, Holopainen et al. 2003, 
Moilanen et al. 2003, Liu et al. 2005). The 
main activation of proMMP-2 takes place 
on the cell surface and is mediated through 
a trimolecular complex of MMP-2/TIMP-2/
MMP-14 (Strongin et al. 1995). In addition, 
certain MMPs such as MT-MMPs, MMP-
11, MMP-23, and MMP-28 possess a furin 
cleavage site, and are likely to be activated 
intracellularly by furin-like pro-protein 
convertases and are secreted or bond to the 
cell surface as active enzymes (Nagase et al. 
2006). 
2.2.1. Inhibition of MMPs
The activity of MMPs is inhibited by both 
endogenous and synthetic MMP inhibitors, 
being physiologically inhibited by speciﬁc 
tissue inhibitors of metalloproteinases 
(TIMPs) as well as by the broad-spectrum 
proteinase inhibitor α
2
-macroglobulin, the 
major inhibitor of MMPs in plasma (Baker 
et al. 2002). 
TIMPs. TIMPs are relatively small 20 
to 30-kD proteins that bind MMPs in a 
1:1 stoichiometric ratio and in a reversible 
manner. To date, four TIMPs have been 
characterized in humans (TIMP-1, -2, -3, 
and -4). The TIMPs inhibit active forms of 
all MMPs without major selectivity, although 
TIMP-1 is a poor inhibitor of certain MT-
MMPs and MMP-19 (Lambert et al. 2004). 
In addition, the TIMPs are also able to 
make complexes with proMMPs: TIMP-1 
preferentially binds to proMMP-9, and TIMP-
2 with proMMP-2, which is important in the 
cell-surface activation of proMMP-2. TIMP-
3 makes complexes with both proMMP-2 and 
proMMP-9, whereas TIMP-4 has the ability 
to bind proMMP-2 (Lambert et al. 2004). 
Expression of TIMP-1 and TIMP-3 can be 
induced by a variety of cytokines and growth 
factors, whereas TIMP-2 is constitutively 
expressed in many cell types (Baker et al. 
2002). In the healthy adult mouse, TIMP-
2 is expressed at high levels in all tissues 
(Nuttall et al. 2004). It directly suppresses 
endothelial cell growth and angiogenesis, and 
this function is independent of its ability to 
inhibit MMP activity (Stetler-Stevenson and 
Seo 2005). Other TIMPs also show MMP-
independent functions such as regulation of 
cell growth and apoptosis (Lambert et al. 
2004). 
Synthetic inhibitors of MMPs. Numerous 
synthetic MMP inhibitors have been 
developed, most of which target the catalytic 
site of the MMPs and act by chelating the 
active site zinc ion (Birkedal-Hansen et al. 
1993). The MMP inhibitors can be divided into 
3 major classes: peptidomimetic inhibitors, 
non-peptidomimetics, and tetracycline 
analogues. Some of them have been evaluated 
in clinical trials, mainly as a treatment option 
for cancer or rheumatoid arthritis, but the 
results have been disappointing (Coussens 
et al. 2002, Ala-aho and Kähäri 2005). The 
only MMP inhibitor in clinical use is low-
dose doxycycline as adjunctive medication 
in human periodontal disease (Golub et al. 
1998). Chemically modiﬁed tetracyclines 
(CMTs) are tetracycline analogues devoid of 
antimicrobial activity, which inhibit MMPs 
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by chelating the active site zinc ion, rendering 
the MMPs more susceptible to degradation, 
as well as by down-regulating MMP mRNA 
expression (Golub et al. 1998). Tetracyclines 
also inhibit neutrophil elastase and are capable 
of scavenging reactive oxygen species and 
inhibiting cytokine expression (Nieman and 
can cause ECM destruction either directly 
or indirectly by activating proMMPs such as 
MMP-9 (Watanabe et al. 1993, Ferry et al. 
1997), as well as enhancing MMP activity by 
degrading and inactivating TIMPs (Itoh and 
Nagase 1995). Moreover, neutrophil elastase 
may mediate inﬂammation by inducing the 
secretion of proinﬂammatory cytokines 
(Nakamura et al. 1992). 
The activity of neutrophil serine 
proteinases is controlled by serine proteinase 
inhibitors known as serpins, such as α
1
-
proteinase inhibitor (also known as α
1
-
antitrypsin), α
1
-antichymotrypsin, secretory 
leukocyte proteinase inhibitor (SLPI), and 
elaﬁn (Wewers et al. 1988, Weiss 1989, 
Hiemstra 2002, Sallenave 2002), as well 
as by α
2
-macroglobulin which reacts with 
a large variety of proteinases (Wewers et 
al. 1988). SLPI and elaﬁn are produced 
locally at mucosal sites, while the liver is 
the main source of α
1
-proteinase inhibitor, 
α
1
-antichymotrypsin, and α
2
-macroglobulin 
(Sallenave 2002). Several studies have 
indicated that elaﬁn, SLPI, and α
1
-proteinase 
inhibitor may affect the inﬂammatory 
response also by mechanisms distinct from 
those associated with the antiproteolytic 
activity against leukocyte-derived serine 
proteinases (Churg et al. 2001, Hiemstra 
2002, Sallenave 2002). 
Zerler 2001). Studies in animal models of 
septic shock and ARDS have suggested that 
prophylactic treatment with CMT-3 may 
reduce morbidity in patients at risk for sepsis 
or ARDS (Carney et al. 1999, Nieman and 
Zerler 2001, Steinberg et al. 2005).
Serine proteinases comprise a large family 
proteolytic enzymes characterized by a serine 
residue at their active site. These enzymes 
regulate various biological functions, 
including coagulation, ﬁbrinolysis, immune/
inﬂammatory responses, digestion of dietary 
proteins, and degradation of ECM and BM. 
Inﬂammatory cell-derived serine 
proteinases.  Inﬂammatory cells such as 
neutrophils, monocytes, and mast cells are 
signiﬁcant stores of serine proteinases. Mast 
cell granules contain chymase and tryptase, 
both of which are released from mast cells 
during inﬂammation and allergic reactions 
(Sommerhoff 2001). Neutrophil elastase, 
cathepsin G, and proteinase 3 are produced 
during neutrophil development and stored in 
the primary granules of mature neutrophils. 
When the neutrophils are activated, these 
proteinases are released by degranulation into 
the extracellular space (Weiss 1989), although 
some of the elastase and cathepsin G remain 
bound to the neutrophil plasma membrane, 
where the enzymes are active and resistant 
to inhibition by antiproteinases (Owen et al. 
1995).  Neutrophil serine proteinases have a 
broad substrate speciﬁcity, and when released 
into the extracellular space in excessive 
amounts during inﬂammation they have the 
potential to cause tissue injury  (Hiemstra 
et al. 1998, Lee and Downey 2001, Shapiro 
2002). Neutrophil elastase and cathepsin G 
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Fibrinolytic serine proteinases. The 
serine proteinases of the ﬁbrinolytic system 
consist of plasminogen/plasmin and speciﬁc 
plasminogen activators (PA) (Vassalli et al. 
1991). Inhibition of these ﬁbrinolytic serine 
proteinases may occur either at the level of 
the PA, by speciﬁc plasminogen activator 
inhibitors (PAI-1 and PAI-2), or at the level 
of plasmin, mainly by α
2
-antiplasmin (Lijnen 
2001). In the vasculature, tissue-type PA 
(tPA) bound to ﬁbrin generates plasmin 
for thrombolysis. Cell surface-associated 
plasmin, generated by the activity of receptor-
bound urokinase type PA (uPA) on cell bound 
plasminogen, is believed to be involved 
in the degradation of the ECM. It activates 
several latent MMPs, notably MMP-3 and 
MMP-9 (Mazzieri et al. 1997, Murphy et al. 
1999, Liu et al. 2005), and is also capable of 
directly degrading ECM components such as 
ﬁbronectin, vitronectin, or laminin (Danø et 
al. 1985). 
3.1. Trypsinogens and their inhibitors
Pancreatic trypsinogen is a well-characterized 
digestive serine proteinase. Several 
trypsinogen isoforms have been identiﬁed 
in humans (Scheele et al. 1981, Wiegand 
et al. 1993) and in several animal species 
including rat (Brodrick et al. 1980, Lütcke 
et al. 1989). The human pancreas produces 
three trypsinogen isoenzymes which differ 
in isoelectric point, namely trypsinogen-
1 (cationic trypsinogen), trypsinogen-2 
(anionic trypsinogen), and a minor isoform, 
trypsinogen-3 (mesotrypsinogen) (Scheele 
et al. 1981, Rinderknecht et al. 1984). In 
addition, trypsinogen-4, a splicing variant 
of trypsinogen-3, has been identiﬁed in the 
human brain (Wiegand et al. 1993). 
Extrapancreatic trypsinogen. Trypsinogen-
1 and -2 were detected and characterized 
for the ﬁrst time outside the gastrointestinal 
tract in the cyst ﬂuid of human ovarian 
tumors (Stenman et al. 1988). These tumor-
associated trypsinogens are identical to the 
pancreatic trypsinogen-1 and -2 in amino 
acid sequences, in immunoreactivity, 
and in molecular size (25 kD and 28 kD, 
respectively), but display minor differences 
in substrate speciﬁcity and susceptibility to 
inhibition by protease inhibitors (Koivunen et 
al. 1989). Trypsinogen expression has more 
recently been observed in several tumors 
(Kawano et al. 1997, Fujimura et al. 1998) 
as well as in cancer cell lines (Koivunen 
et al. 1991). Trypsinogen is now known 
to be widely expressed in normal human 
extrapancreatic tissues. At the mRNA and 
protein level, trypsinogen occurs in vascular 
endothelial cells (Koshikawa et al. 1997) and 
in the epithelial cells of the skin, esophagus, 
stomach, small intestine, lung, kidney, liver, 
and extrahepatic bile duct, as well as in 
leukocytes in the spleen and in brain nerve 
cells (Koshikawa et al. 1998). Despite its wide 
distribution in various tissues, however, little 
is known about the regulation of trypsinogen 
expression. 
3.1.1. Regulation of trypsin activity
Activation. During the digestive process, 
trypsinogens are secreted from the pancreas 
into the lumen of the duodenum, where they are 
activated by enterokinase (enteropeptidase). 
In humans, enterokinase is not known to 
occur in tissues other than the intestine. In the 
rat, expression of enterokinase has also been 
observed in the stomach, colon, and brain 
(Yahagi et al. 1996). In vitro, trypsinogen 
can be activated by lysosomal hydrolases 
(Figarella et al. 1988), and incubation of 
stimulated leukocytes with trypsinogen 
has been shown to convert trypsinogen to 
trypsin (Hartwig et al. 1999). At present it 
is, however, unclear how extrapancreatic 
trypsinogens are activated in vivo.
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Inhibition. Activity of trypsin is controlled 
by several inhibitors such as α
1
-antitrypsin, 
α
2
-macroglobulin (Ohlsson 1988), and 
pancreatic secretory trypsin inhibitor (PSTI), 
also called tumor-associated trypsin inhibitor 
(TATI) (Huhtala et al. 1982). PSTI/TATI, 
a highly speciﬁc inhibitor of trypsin with a 
molecular weight of 6 kD, was originally 
found in the pancreas, but has subsequently 
been identiﬁed in a variety of human tissues, 
including the gastrointestinal tract and lung 
(Shibata et al. 1987). Although the main role 
of PSTI/TATI is thought to be protection 
of the tissue from the destructive activity 
of trypsin, PSTI/TATI may also play a role 
in maintaining mucosal integrity and in 
stimulating epithelial repair (Marchbank et 
al. 1998). 
 3.1.2. Functions of trypsin 
Human trypsin is a potent matrix-degrading 
proteinase, which directly degrades various 
components of the ECM and BM, including 
ﬁbronectin and collagen types I, II, and IV 
(Koivunen et al. 1991, Koshikawa et al. 1992, 
Moilanen et al. 2003, Stenman et al. 2005). 
Moreover, trypsin-2 efﬁciently activates 
latent proforms of MMP-1, -3, -8, -9, and -13 
in vitro at very low concentrations (Sorsa et 
al. 1997, Moilanen et al. 2003), and partially 
activates MMP-2 (Sorsa et al. 1997). Human 
trypsin-1 and -2 are also activators of the 
proform of u-PA (Koivunen et al. 1989).
The wide distribution of trypsin expression 
in the intact epithelium of several human 
tissues suggests that it functions in common 
homeostatic processes. Trypsin is a potent 
activator of proteinase-ativated receptor 
2 (PAR
2
), which is extensively expressed 
in the epithelial cells and is believed to 
be involved in various physiological and 
pathophysiological functions (Dery et al. 
1998, Steinhoff et al. 2005). 
In the intestine, human α-defensin 5 (HD5) 
is a key contributor to microbial defense 
(Ouellette and Selsted 1996). It is stored 
as a propeptide in healthy ileal mucosa; to 
be fully functional, it must be processed 
proteolytically after its secretion (Cunliffe 
et al. 2001).  Recently, it was found in that 
Paneth cells of the human terminal ileum 
produce trypsinogen-2 and -3 and the 
pro-ΗD5, and that trypsin is the cleaving 
enzyme for HD5 in vivo (Ghosh et al. 2002). 
Therefore, as a prodefensin convertase in 
human Paneth cells, trypsin is believed to be 
involved in the innate immunity of the human 
small intestine. 
3.2. Serine proteinase signaling by 
activation of proteinase-activated receptors 
(PAR)
The serine proteinases act, at least in part, 
via proteinase-activated receptors, a family 
of G-protein-coupled seven-transmembrane 
receptors that are expressed in a variety of 
tissues, including lung, gastrointestinal tract, 
cardiovascular system, skin, and nervous 
system (Dery et al. 1998, Steinhoff et al. 
2005). Four members of the PAR family have 
been cloned and characterized in humans and 
murines, thus far (Vu et al. 1991, Nystedt et 
al. 1994, 1995, Ishihara et al. 1997, Xu et 
al. 1998). The general mechanism by which 
proteinases activate PARs is the same: They 
cleave at speciﬁc sites within the extracellular 
amino terminus of the receptor (Dery et al. 
1998). The newly exposed amino terminus 
itself acts as a tethered ligand which binds to 
conserved regions in the second extracellular 
loop of the cleaved receptor, resulting in 
receptor activation and initiation of multiple 
signaling cascades with diverse consequences 
such as hemostasis, inﬂammation, pain 
transmission, and repair (Macfarlane et 
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al. 2001, Hollenberg and Compton 2002, 
Ossovskaya and Bunnett 2004, Steinhoff et 
al. 2005) (Figure 3). 
Of the serine proteinases, thrombin 
activates PAR
1
, PAR
3
, and PAR
4
–but not 
PAR
2
 (Vu et al. 1991, Ishihara et al. 1997, 
Xu et al. 1998), which is cleaved by trypsin 
(Nystedt et al. 1994). Although PAR
1
, PAR
3
, 
and PAR
4 
are considered predominantly to be 
thrombin receptors, they can also be activated 
by trypsin (Hollenberg and Compton 2002), 
and PAR
4
 by cathepsin G (Sambrano et al. 
2000). All PARs except PAR
3
 can also be 
activated by short synthetic peptides (PAR-
activating peptides) that mimic the tethered 
ligand region of the receptor (Macfarlane et 
al. 2001). Activation of PARs by proteinases 
is irreversible, and once cleaved, the 
receptors are endocytosed and trafﬁcked to 
lysosomes for degradation (Ossovskaya and 
Bunnett 2004). In addition to the activating 
cleavage, cell-surface proteolysis may 
disable PARs by removing or destroying the 
tethered ligand, and thus prevent receptor 
activation. Neutrophil elastase and cathepsin 
G can disarm PAR
1
 and PAR
2
, and in this way 
dampen signaling by activating proteinases 
(Dulon et al. 2003, Ossovskaya and Bunnett 2004). 
3.2.1. PAR
2
Pancreatic trypsin, and extrapancreatic 
trypsin-2, as well as human recombinant 
trypsin-1 and -2 very potently activate PAR
2 
(Nystedt et al. 1994, Alm et al. 2000, Grishina 
et al. 2005). PAR
2
 is also activated by mast 
cell tryptase, although considerably less 
potently than by trypsin (Corvera et al. 1997, 
Alm et al. 2000). The coagulation factors 
FVIIa and FXa also function as activators 
when anchored by tissue factor to the cell 
surface (Camerer et al. 2000). 
Figure 3. Mechanism of activation of proteinase-activated receptors (PARs). The “tethered ligand” 
sequence (hatched box) which is revealed following enzyme-speciﬁc cleavage, binds to a site on the 
second extracellular loop (grey box), to initiate G-protein-mediated cell signalling.  Synthetic peptide 
mimetics of the PARs tethered ligand sequences are able to activate PARs by binding to the receptor (grey 
box) without proteolytic cleavage of the aminoterminus. Modiﬁed from Cocks and Moffatt (2000). 
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Like trypsin, PAR
2
 is highly expressed 
in the lung, skin, kidney, gastrointestinal 
tract, and brain, where it is found in 
epithelial and endothelial cells, myocytes, 
ﬁbroblasts, inﬂammatory cells, and neurons 
(D’Andrea et al. 1998). It is involved in 
both cytoprotective and proinﬂammatory 
responses (Cocks et al. 1999, Steinhoff et 
al. 2005). It plays a protective role in the 
gastric mucosa (Kawabata 2003), while in 
the intestine and lung it appears to play both 
pro- and anti-inﬂammatory roles (Cocks et 
al. 1999, Kawabata 2003). 
The role of PAR
2
 in inﬂammation has 
been suggested by its up-regulation by 
inﬂammatory mediators such as TNF-α and 
Controlled remodeling and degradation 
of ECM by matrix proteinases, especially 
MMPs, are essential for lung development 
and growth as well as for its function as the 
organ of ventilation (Chua et al. 2005, Ryu et 
al. 2005). In addition to matrix degradation 
and turnover, these enzymes function in the 
lung as regulators of inﬂammation, innate 
immunity, apoptosis, and repair (Lee and 
Downey 2001, Li et al. 2002, Shapiro 2002, 
McMillan et al. 2004, Parks et al. 2004). 
In the healthy adult lung, proteinase 
inhibitors are present in higher concentrations 
than are matrix-degrading proteinases, 
and thus prevent the deleterious effects on 
tissue. However, during lung inﬂammation, 
the release of large amounts of proteolytic 
enzymes by inﬂammatory as well as by 
activated lung resident cells may result 
in dysregulated extracellular proteolysis 
leading to development of tissue damage 
IL-α  (Nystedt et al. 1996). Its activation
 
leads to increased vascular permeability 
and leukocyte margination and inﬁltration 
(Vergnolle et al. 1999, Vergnolle 1999), as 
well as to the production of proinﬂammatory 
cytokines and MMP-9 (Vliagoftis et al. 
2000, Asokananthan et al. 2002). The 
proinﬂammatory effects of PAR
2
 activation 
are at least in part mediated by a neurogenic 
mechanism (Steinhoff et al. 2000). Recent 
studies using PAR
2
 knockout mice suggest a 
critical role for this receptor in inﬂammation 
of the lung, joints, and intestine (Ferrell et 
al. 2003, Hansen et al. 2005, Kelso EB et al. 
2006, Su et al. 2005). 
4. MATRIX PROTEINASES IN THE LUNG
(Lee and Downey 2001, Chua et al. 2005). 
Moreover, MMPs and serine proteinases 
are involved in the chemotaxis of various 
inﬂammatory cells and in growth factor 
bioavailability and may thus have a major 
impact on the overall level of inﬂammation 
and play a role in ﬁbroproliferative lung 
repair following injury (Parks et al. 2004, 
Chua et al. 2005). Increased pulmonary 
levels of matrix-degrading proteinases and an 
imbalance between these enzymes and their 
inhibitors are associated with lung injury in 
preterm infants as well as with several acute 
and chronic inﬂammatory lung diseases in 
adults (Merritt et al. 1983, Ricou et al. 1996, 
Lee and Downey 2001, Prikk et al. 2002, 
Chakrabarti and Patel 2005).
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4.1. MMPs and tissue inhibitors of 
metalloproteinases (TIMPs) in the lung
4.1.1. MMPs and TIMPs in lung 
development 
In contrast to the adult human lung, which 
exhibits a high antiproteinase to proteinase 
ratio, the fetal human lung is characterized 
by a dominant proteolytic proﬁle enabling 
rapid remodeling of the ECM during lung 
development (Ryu et al. 2005). During 
fetal and early postnatal lung development, 
several MMPs and TIMPs are expressed 
(Fukuda et al. 2000, Masumoto et al. 2005, 
Ryu et al. 2005). In the developing rabbit 
lung, MMP-1, -2, -9, and -14 and TIMP-
2 are immunohistochemically localized in 
epithelial cells, and MMP-2 and TIMP-2 also 
in mesenchymal cells (Fukuda et al. 2000). 
In the mouse fetal lung, high levels of RNA 
have been demonstrated for MMP-2 and 
-14, as well as for TIMP-2, and -3 (Nuttall 
et al. 2004). By in situ hybridization, MMP-
14 and TIMP-2 are localized in epithelial 
and mesenchymal cells, but MMP-2 only 
in mesenchymal cells (Kheradmand et al. 
2002). During human fetal lung development, 
expression of MMP-1 and -9, as well as 
TIMP-1, -2, and -3 has been detected 
immunohistochemically in lung epithelial 
cells and vascular endothelial and smooth 
muscle cells, but expression of MMP-2 only 
in vascular endothelial and smooth muscle 
cells (Masumoto et al. 2005). Expression 
of MMP-1, -2, -8, and -9 has recently been 
studied during lung development of the 
fetal baboon, showing an increase in protein 
levels of MMP-1 and -9 with advancing 
gestation, and an increase in MMP-8 level 
during early gestation and then a decrease 
during the late phase of lung development, 
whereas it showed MMP-2 levels to remain 
high throughout gestation  (Tambunting et al. 
2005).
Several studies have demonstrated an increase 
in type IV collagenolytic activity during late 
fetal lung development as well as during the 
early phase of postnatal lung growth (Arden 
and Adamson 1992, Arden et al. 1993, Fukuda 
et al. 2000). This has been attributed mainly 
to increased levels of active MMP-2 (Arden 
et al. 1993, Fukuda et al. 2000), although 
MMP-9 may also be involved (Fukuda et al. 
2000, Hosford et al. 2004). The signiﬁcance 
of MMP-9 appears to be limited, however, 
since mice deﬁcient in MMP-9 have normal 
branching morphogenesis and develop normal 
adult lungs (Atkinson and Senior 2003). In 
contrast, MMP-2 null mice and mice deﬁcient 
in its activator MMP-14 exhibit abnormal 
branching morphogenesis and alveolarization 
(Kheradmand et al. 2002, Atkinson et al. 
2005). Among the TIMPs, TIMP-3 may play 
an important role in regulating MMP activity 
during lung development, as demonstrated 
by impaired branching morphogenesis and 
progressive air space enlargement in TIMP-3 
null mice, a phenomenon believed to be at 
least in part caused by excessive ﬁbronectin 
fragmentation (Gill et al. 2003). 
4.1.2. MMPs and TIMPs in lung injury in 
the preterm infant 
After the beginning of this thesis project, 
several investigators have reported data 
describing the presence of MMPs and TIMPs 
in tracheal aspirates from ventilated preterm 
infants during the early postnatal period 
(Danan et al. 2002, Ekekezie et al. 2004) 
and in their BALF samples (Schock et al. 
2001, Sweet et al. 2001, Curley et al. 2003, 
2004, Sweet et al. 2004). Increased levels 
of MMP-8 and -9 were detected in preterm 
infants from pregnancies complicated by 
chorioamnionitis (Curley et al. 2003, Curley 
et al. 2004). A signiﬁcant positive correlation 
has been observed between protein carbonyl 
concentrations and MMP-9 and TIMP-1 
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concentrations in BALF (Schock et al. 2001) 
suggesting that MMP-9 and TIMP-1 can be 
up-regulated by oxidative stress in preterm 
infants early postnatally. During the ﬁrst few 
days of life, low MMP-2 (Danan et al. 2002, 
Ekekezie et al. 2004), high MMP-8 (Sweet 
et al. 2001), low TIMP-1 and -2 (Ekekezie et 
al. 2004), and a high MMP-9/TIMP-1 ratio 
(Ekekezie et al. 2004) have been associated 
with later development of BPD. In addition, 
Ekekezie et al. (2004) showed that the ratio 
of MMP-9 to TIMP-1 remains signiﬁcantly 
higher during the ﬁrst two postnatal weeks 
in preterm infants who subsequently develop 
BPD than in those who survive without it, 
but with no difference in levels of MMP-9 
between groups. 
In autopsy lung specimens from preterm 
infants with RDS or in different phases of 
BPD, immunohistochemical expression of 
MMP-1, TIMP-1, and -2 appears in alveolar 
type-II epithelial cells as well as in alveolar 
macrophages. In addition, in the chronic 
phase of BPD, immunoreactivity for MMP-
1, TIMP-1, and -2 also appears in ﬁbroblasts 
of ﬁbrotic foci (Dik et al. 2001).
4.1.3. MMPs and TIMPs in animal models 
of BPD 
Prolonged exposure of newborn mice 
and rats to hyperoxia results in chronic 
lung injury characterized by decreased 
alveolarization, progressive inﬂammation, 
edema, and increased septal and interstitial 
thickness (Warner et al. 1998, Wagenaar et 
al. 2004). In lungs of neonatal rats exposed 
to >95% of hyperoxia from postnatal day 4 
to 14, decreased expression of both MMP-9 
mRNA and protein occurred, and, conversely, 
an increase in TIMP-1 mRNA and protein 
when compared with animals raised in room 
air (Hosford et al. 2004). In neonatal rats 
exposed to hyperoxia from birth, several 
studies have, during the ﬁrst few postnatal 
days, shown increased expression and activity 
of MMP-2 (Devaskar et al. 1994, Buckley 
and Warburton 2002, Wagenaar et al. 2004) 
and MMP-9 (Buckley and Warburton 2002), 
as well as increased expression of MMP-12 
when compared with control rats (Wagenaar 
et al. 2004). During hyperoxia, no changes in 
the expression of TIMP-2 have been observed 
either at protein (Buckley and Warburton 
2002) or mRNA level (Hosford et al. 2004). 
Recently, a study of MMPs and TIMPs 
in an extremely premature-baboon model 
of BPD demonstrated signiﬁcantly higher 
protein levels of MMP-9 and a higher ratio of 
MMP-9 to TIMP-1 in lungs of these baboons 
when compared with gestational controls 
(Tambunting et al. 2005). In baboons with 
BPD, pulmonary levels of MMP-8 were 
signiﬁcantly lower, with no differences 
detectable in levels of MMP-2 (Tambunting 
et al. 2005). 
4.1.4. MMPs and TIMPs in acute lung injury 
in adults
Elevated levels of MMP-2 and especially 
of MMP-9 occur in BALF from patients 
with ARDS (Ricou et al. 1996, Torii et al. 
1997, Pugin et al. 1999). Although TIMP-1 
in BALF is increased in ARDS (Ricou et al. 
1996, Torii et al. 1997), the ratio of MMP-
9 to TIMP-1 in BALF remains elevated 
in late phases of prolonged ARDS (Ricou 
et al. 1996). Thus, an imbalance between 
MMP-9 and TIMP-1 may play a role in the 
pathogenesis of ARDS.
Increased activities for MMP-2 and MMP-
9 in BALF and lung exist in various animal 
models of hyperoxic lung injury (Pardo 
et al. 1996, Pardo et al. 1998, Melendez et 
al. 2000, Gushima et al. 2001). In addition, 
collagenolytic activity in BALF is increased 
in rats exposed to 100% oxygen for 60 hours 
(Pardo et al. 1996). During hyperoxic lung 
injury, MMP-2 and MMP-9 mRNA and 
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protein are mainly localized in alveolar 
epithelial cells and alveolar macrophages 
(Pardo et al. 1996, Gushima et al. 2001). 
Exposure to hyperoxia elevates expression 
of TIMP-1, but not TIMP-2 mRNA (Pardo 
et al. 1998, Melendez et al. 2000). Similarly 
to MMP-2 and MMP-9, TIMP-1 and -2 are 
mainly localized in alveolar macrophages 
and alveolar epithelial cells during hyperoxia 
(Pardo et al. 1998, Melendez et al. 2000). 
A novel anti-inﬂammatory role for 
neutrophil-derived MMP-8 has recently 
been observed in lipopolysaccharide (LPS)-
mediated acute lung injury in mice (Owen 
et al. 2004). A greater accumulation of 
neutrophils in the alveolar space occurred 
24 hours after intratracheally administrated 
LPS in MMP-8 -/- mice than in wild-type 
controls. The investigators later show that 
the BALF from MMP-8 -/- mice has more 
neutrophil chemotactic activity as well as 
more macrophage inﬂammatory protein-1α 
(MIP-1α) than does BALF from wild-type 
mice after LPS exposure (Owen et al. 2005). 
In vitro, membrane-bound MMP-8 totally 
degraded MIP-1α, reducing its neutrophil 
chemotactic activity, whereas soluble MMP-
8 cleaved MIP-1α only partially (Owen et al. 
2005). 
MMP-7 is constitutively expressed in 
intact human airway epithelium, and its 
expression is induced in injured epithelium, 
where it plays an important role in re-
epithelisation by facilitating epithelial-
cell migration (Dunsmore et al. 1998). In 
addition, epithelial-derived MMP-7 regulates 
chemokine mobilization and transepithelial 
efﬂux of neutrophils in bleomycin-injured 
murine lungs by causing shedding of the 
ectodomain of syndecan-1 (Li et al. 2002).
Deﬁciency in TIMP-1, as recently 
shown, aggravates acute bleomycin-induced 
lung injury as determined by enhanced 
pulmonary neutrophilia, hemorrhage, and 
vascular permeability (Kim et al. 2005). 
Levels of MMP-9 were higher in BALF 
from TIMP-1 null mice, with no difference 
in BALF chemotactic activity between 
genotypes. TIMP-1 may thus play an 
important role during acute lung injury in 
preserving the alveolar-capillary barrier from 
proteolytic damage (Kim et al. 2005). 
In addition to TIMP-1, TIMP-2 plays an 
important role in regulating the intensity 
of lung inﬂammatory injury (Mulligan et 
al. 1993, Gibbs et al. 1999, Gipson et al. 
1999). In rat models of both macrophage-
dependent and neutrophil-dependent acute 
lung injury, intratracheally administered 
human recombinant TIMP-2 (Mulligan 
et al. 1993, Gibbs et al. 1999) inhibits 
pulmonary damage. Affecting the generation 
of the powerful chemoattractant complement 
anaphylatoxin C5a in the lung may be one 
mechanism by which TIMP-2 regulates lung 
inﬂammation (Gipson et al. 1999).
4.1.5. MMPs and TIMPs in chronic 
inﬂammatory airway diseases in adults
Sustained, elevated expression of MMP-2 or 
MMP-9, or both and altered expression of 
TIMPs exists in chronic pulmonary diseases 
such as asthma, chronic obstructive pulmonary 
disease, and idiopathic pulmonary ﬁbrosis 
(Chakrabarti and Patel 2005). Smokers with 
emphysema show higher levels of MMP-
8 and MMP-9 in BALF than do smokers 
without emphysema (Betsuyaku et al. 1999). 
BALF from adult patients with asthma or 
bronchiectasis contains elevated levels and 
a higher degree of activation of MMP-8 
than does BALF from healthy controls, and 
in these diseases, MMP-8 localized at both 
the protein and mRNA level in bronchial 
epithelial cells, macrophages, and neutrophils 
(Prikk et al. 2001a, Prikk et al. 2002).  In 
addition, the level and activation degree of 
MMP-8 in BALF were higher in patients 
with severe asthma than in those with well-
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controlled asthma, and an inverse correlation 
existed with airﬂow obstruction, indicating a 
direct connection between MMP-8 activity 
and deterioration in lung function (Prikk et 
al. 2002).   
The role of MMP-8 in asthma-related 
acute airway inﬂammation has recently 
been studied in an ovalbumin-sensitized 
mouse model of asthma using MMP-8 -/- 
and WT mice (Gueders et al. 2005). In this 
model, MMP-8 deﬁciency was, following 
allergen exposure, associated with increased 
numbers of neutrophils in BALF, and 
enhanced migration of neutrophils as well as 
eosinophils in the airway walls. Assessment 
of cell apoptosis demonstrated signiﬁcantly 
reduced neutrophil apoptosis in MMP-8 -
/- mice compared to WT mice, suggesting 
that the anti-inﬂammatory effect of MMP-8 
is in part due to a role in the regulation of 
neutrophil apoptosis (Gueders et al. 2005). 
Variable effects of MMP-9 on allergen-
induced airway inﬂammation have been 
recently observed in MMP-9 knockout 
animals. Vermaelen et al. (2003) demonstrated 
reduced inﬁltration of inﬂammatory cells into 
the airways after allergic challenge in MMP-9 
-/- mice. The study of McMillan et al. (2004), 
using an exposure protocol based on high 
allergen concentrations, showed in contrast, 
increased inﬂammatory cell inﬁltrate in both 
bronchial mucosa and BALF from MMP-9 
null mice.
4.2. Serine proteinases and their inhibitors 
in the lung 
4.2.1. Inﬂammatory cell-derived serine 
proteinases and their inhibitors
The major sources of serine proteinases 
in the lung are inﬂammatory cells such as 
neutrophils, mast cells, and macrophages 
(Lee and Downey 2001, Sommerhoff 2001). 
Neutrophil elastase has several detrimental 
effects on lung tissue: It is capable of 
degrading almost all components of ECM, it 
is directly cytotoxic to endothelial cells, and 
it has various proinﬂammatory effects (Lee 
and Downey 2001, Shapiro 2002). 
Increased levels of neutrophil elastase 
together with reduced functional activity of 
its inhibitor α
1
-antitrypsin have been detected 
in the airway secretions from preterm infants 
with RDS and from those who subsequently 
develop BPD (Merritt et al. 1983, Speer 
et al. 1993). During inﬂammation, α
1
-
antitrypsin is inactivated both oxidatively 
by reactive oxygen species released from 
inﬂammatory cells (Carp and Janoff 1980) 
and proteolytically by several MMPs, 
including MMP-8 and -9 (Liu et al. 2000, 
Owen et al. 2004). In the developing lung, 
elastic ﬁbers provide structural support for 
alveolar septal development (Roth-Kleiner 
and Post 2005). Thus, in preterm infants with 
BPD elastolytic damage may be a signiﬁcant 
factor in the impaired lung development. In 
neonatal rats, α
1
-antitrypsin protects against 
the toxic effects of oxygen on pulmonary 
parenchymal and vascular development 
(Koppel et al. 1994). Furthermore, in a 
randomized, controlled trial, prophylactic 
administration of α
1
-antitrypsin intravenously 
into preterm infants with RDS has reduced the 
incidence of pulmonary hemorrhage and the 
use of inhaled steroids and bronchodilators, 
although the reduction in risk for BPD at 36 
gestational weeks failed to reach statistical 
signiﬁcance (Stiskal et al. 1998).
An imbalance between neutrophil 
elastase and its inhibitors in the lung has 
also been implicated in adult inﬂammatory 
lung diseases, such as emphysema, chronic 
obstructive pulmonary disease, and ARDS 
(Moraes et al. 2003).
Serine proteinase tryptase is a major 
mast cell-derived proteinase believed to 
be involved in airway inﬂammation and 
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remodeling associated with ﬁbroproliferative 
lung diseases such as asthma and chronic 
obstructive pulmonary disease (Sommerhoff 
2001, Cairns 2005). The increased numbers of 
mast cells appearing in autopsy lung samples 
from preterm infants with long-standing 
BPD suggests that, in the development of 
BPD, tryptase may also play a role (Lyle et 
al. 1995). Tryptase induces proliferation of 
pulmonary ﬁbroblasts and airway smooth 
muscle cells, and induces secretion of 
proinﬂammatory mediators by bronchial 
epithelial cells (Sommerhoff 2001, Cairns 
2005). It is also capable of digesting 72-
kD gelatinase into a 62-kD form, as well as 
degrading ﬁbronectin, suggesting that it may 
play a role in the degradation of ECM (Lohi 
et al. 1992). Many of the cellular effects 
of tryptase may be mediated through PAR
2
 
cleavage and activation (Akers et al. 2000, 
Berger et al. 2001, Cairns 2005). 
4.2.2. Trypsin and trypsin-like proteinases
In the lung, in addition to inﬂammatory 
cells, resident cells are also an important 
source of serine proteinases. Extrapancreatic 
trypsin has been identiﬁed at both the mRNA 
and protein level in normal adult bronchial 
epithelium (Koshikawa et al. 1998, Cocks et 
al. 1999), and recently, trypsin was identiﬁed 
in rat lung (Towatari et al. 2002). Little is 
known, however, about the role of trypsin 
in the lung. Trypsin colocalizes with PAR
2
 
in the epithelium of human bronchioles, and 
has been suggested to be the physiologic 
activator of pulmonary epithelial PAR
2
 
(Cocks et al. 1999). By activating PAR
2
, 
trypsin may play a cytoprotective and, on 
the other hand, also a harmful role (Cocks 
et al. 1999, Ossovskaya and Bunnett 2004). 
In addition, if dysregulated, trypsin may 
cause pulmonary tissue destruction through 
direct degradation of ECM and BM proteins 
(Koivunen et al. 1991, Koshikawa et al. 1992, 
Moilanen et al. 2003, Stenman et al. 2005), 
as well as through activation of various 
proMMPs (Sorsa et al. 1997, Moilanen et 
al. 2003). In BALF from adult patients with 
chronic inﬂammatory airway diseases the 
levels of trypsin-2-α
1
-antitrypsin complex 
correlate with the activation level of MMP-9 
and of type I collagenolytic activity (Prikk et 
al. 2001b). 
A novel serine proteinase called human 
airway trypsin-like protease (HAT) has been 
characterized in adult human lung (Yamaoka 
et al. 1998) and immunolocalized in ciliated 
cells of the bronchial epithelium (Takahashi et 
al. 2001). HAT is synthesized as a membrane-
bound precursor with a molecular size of 48 
kD which is then proteolytically converted 
at the cell surface into a 27-kD mature form, 
and then released into the mucous membrane 
(Yamaoka et al. 1998). On the basis of its 
structure, the HAT precursor is believed to 
be a member of the type II transmembrane 
serine proteinase family (Hooper et al. 2001). 
HAT may play a physiological role within the 
airway epithelium, but it may also become 
involved in airway remodeling by stimulating 
ﬁbroblast proliferation via activation of PAR
2
 
(Matsushima et al. 2006).
4.2.3. PAR
2
All PARs have been immunolocalized in 
human lung epithelial and smooth muscle 
cells (D’Andrea et al. 1998, Knight et al. 
2001, Asokananthan et al. 2002). In the 
mammalian lung, immunoreactive PAR
2
 
is also expressed by ﬁbroblasts, sensory 
neurons, bronchial glands, endothelial cells, 
and vascular smooth muscle cells (D’Andrea 
et al. 1998, Akers et al. 2000, Ricciardolo et 
al. 2000), as well as by migrated inﬂammatory 
cells such as macrophages, neutrophils, mast 
cells, and eosinophils (Steinhoff et al. 2005). 
The endogenous proteinases responsible 
for activating PAR
2
 in the lung await 
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largely determination. Trypsin may act as 
a physiologic activator of epithelial PAR
2
 
(Cocks et al. 1999). Other possible activators 
of PAR
2
 in the lung include mast cell tryptase 
(Cairns 2005), HAT (Matsushima et al. 2006), 
as well as certain nonmammalian proteinases 
such as dust mite allergens (Ossovskaya and 
Bunnett 2004).
In the lung, PAR
2
 may regulate both 
cytoprotective and proinﬂammatory 
pathways (Cocks et al. 1999, Ossovskaya and 
Bunnett 2004). In support of this protective 
role are observations from in vitro studies 
performed on isolated airway preparations 
from the mouse and rat demonstrating that 
activation of PAR
2
 causes an epithelium-
dependent bronchorelaxation, and that this 
effect is mediated by release of prostaglandin 
E
2 
(Cocks et al. 1999). In addition, intranasal 
administration of synthetic PAR
2 
activating 
peptide protects against bronchoconstrictor 
challenges in the rat (Cocks et al. 1999). 
Conversely, activation of PAR
2
 induces 
contraction of guinea pig and human 
intrapulmonary bronchi and bronchioles, the 
main site of resistance to air ﬂow (Ricciardolo 
et al. 2000, Schmidlin et al. 2001). Thus, the 
effect of PAR
2
 activation on airway tone 
depends on the species and experimental 
model used. 
Several studies have indicated that PAR
2
 
plays an important role in the pulmonary 
inﬂammation, as it is markedly up-regulated 
in vitro by early pro-inﬂammatory cytokines 
TNF-α and IL-1α (Nystedt et al. 1996). 
Activation of PAR
2
 in human respiratory 
epithelial cell lines induces release of important 
inﬂammatory mediators including IL-6, IL-
8, and prostaglandin E
2
 (Asokananthan et al. 
2002), as well as  synthesis and release of 
MMP-9 (Vliagoftis et al. 2000). In addition, 
PAR
2
 activation induces proliferation of 
human lung ﬁbroblasts and airway smooth 
muscle cells (Akers et al. 2000, Berger et al. 
2001). These in vitro ﬁndings suggest that 
PAR
2
 may participate in airway remodeling 
and in the ﬁbroproliferation associated 
with pulmonary inﬂammatory diseases. 
Accordingly, increased expression of PAR
2
 
appears in the bronchial epithelium of asthma 
patients (Knight et al. 2001).  Involvement 
of PAR
2
 in airway inﬂammation and 
hyperreactivity has further been supported by 
studies using mice which lack or  overexpress 
human PAR
2 
(Schmidlin et al. 2002, Su et al. 
2005). Recently, Su et al. (2005) showed in 
wild-type mice that intratracheal instillation 
of the PAR
2
 activating peptide, but not the 
PAR
1
 or PAR
4
 activating peptides, induces 
airway constriction, acute lung inﬂammation, 
and protein-rich pulmonary edema in wild-
type mice, but in PAR
2
 -/- mice no responses 
to PAR
2
 activating peptide were detectable. 
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 The aims of the present study were to
•  identify the presence, molecular forms, and degree of activation of MMP-2, MMP-
8, and MMP-9, and their speciﬁc inhibitor TIMP-2 in the lungs of preterm infants by 
evaluating their levels in tracheal aspirate ﬂuid (TAF) samples, and to examine the 
involvement of these MMPs and TIMP-2 in lung injury in the preterm infant.
• study the presence, molecular forms, and concentrations of trypsin and its speciﬁc 
inhibitor TATI in lungs of preterm infants, and to evaluate the role of trypsin in the 
development of BPD. 
• study the protein expression and possible co-localization of trypsin-2 and PAR
2
 in 
the human lung during the perinatal period and in acute and chronic lung injury in 
the preterm infant.
• evaluate the role of MMP-2, MMP-8, and MMP-9, and of trypsin in the development 
of acute lung injury by use of animal model of hyperoxic lung injury. 
AIMS OF THE STUDY
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1. SUBJECTS AND EXPERIMENTAL ANIMALS
1.1. Patients in tracheal aspirate ﬂuid (TAF) studies (I, II)
With the approval of the Ethics Committee of the Hospital for Children and 
Adolescents, University Central Hospital, Helsinki, a total of 48 preterm infants 
with respiratory distress were enrolled between December 1993 and October 1997 
for Studies I and II (Table 1). These preterm infants were treated according to the 
standard protocols in the neonatal intensive care unit of the Hospital for Children 
and Adolescents, University Central Hospital. All were intubated at birth because 
of failure to establish spontaneous ventilation, and during the study period all 
underwent mechanical ventilation. Those with major anomalies were excluded. BPD 
was deﬁned as need for supplemental oxygen at the age of 36 gestational weeks, in 
association with chest radiographic ﬁndings typical for BPD (Shennan et al. 1988). 
MATERIALS AND METHODS
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Table 1. Characteristics of preterm infants  in TAF studies (Studies I and II)
PARAMETER STUDY
I 
16 infants
II 
32 infants
PRENATAL
Proteinuric preeclampsia 3 (19) 11 (34)
Premature rupture of membranes ≥ 24 h 7 (44) 12 (38)
Chorioamnionitis 1 5 (31) 9 (28)
Antenatal betamethasone 12 (75) 27 (84)
AT BIRTH
Cesarean section 12 (75) 21 (66)
Gender (M/F) 8/8 21/11
Gestational age (wks) 
 
27.0 ± 2.0 27.3 ±  2.0
Birth weight (g) 
 
875 ± 246 926 ± 295
Apgar score at 1 min 6 ± 3 5 ± 2 
Umbilical artery pH 7.29 ± 0.07 7.28 ± 0.12
Umbilical artery base excess 
 
-2.1 ± 2.3 -3.1 ± 4.0
POSTNATAL
aAPO2 
2 0.35 ± 0.24 0.27 ± 0.20
Surfactant therapy 9 (56) 22 (69)
Doses of surfactant 1 ± 1 2 ± 1
Indomethacin therapy 12 (75) 28 (88)
Dexamethasone therapy during study period 3 0 15 (47)
Duration of mechanical ventilation (d) 19 ± 19 23 ± 18
BPD 6 (38) 18 (56)
Death 2 (13) 1 (3)
  Data are presented as mean ± SD or as number with percentage in parentheses.
1 Diagnosed on the basis of clinical signs with maternal leukocytosis (white blood cell counts > 15 x 109
  cells/L) or increased concentration of C-reactive protein CRP (> 50 mg/L), or both.
2 Initial arterial to alveolar oxygen tension ratio.
3 Study period was 5 days in Study I and 2 weeks in Study II. In Study II, dexamethasone was started at 
  a mean (± SD)  age of 13 ± 7 days (range: 3-33 days).
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1.2. Autopsied subjects in immunohisto-
chemistry studies (II, III).
Immunohistochemistry studies were done 
with the approval of the National Authority 
for Medicolegal Affairs. A total of 12 fetuses 
aborted between 1997 and 2000, and 34 
infants who died between 1991 and 1998 at 
the University Central Hospital, Helsinki, 
were included in immunohistochemistry 
studies. Of the fetuses, 11 were aborted 
because of clinical suspicion of a major 
extrapulmonary malformation in fetal 
ultrasound examination. One fetus died at 
29 gestational weeks as a result of placental 
ablation. All fetuses had macroscopically and 
microscopically normal lungs. 
Of the 34 infants studied, 29 were born 
prematurely. Of these, 9 died as a result of acute 
RDS (age at death 0 to 3 days), 7 of prolonged 
RDS  (age at death 8 to 16 days), and 8 of 
BPD, deﬁned as in tracheal aspirate studies 
I and II (Shennan et al. 1988). As controls, 
5 newborn infants (gestational ages 22 to 33 
weeks) who died within 1 day after delivery 
for reasons not involving lung pathologic 
conditions were included in Study III. Of 
these, 3 received no mechanical ventilation 
or supplemental oxygen (gestational ages 
22 to 22.7 weeks). Mechanical ventilation 
and supplemental oxygen were administered 
to 2 infants (gestational ages 26.1 and 33.0 
weeks) for 2 and 20 hours, respectively. In 
addition, 5 term infants who had normal lung 
histology and died on postnatal days 1 to 3 
of cardiac anomalies were included in Study 
II.  None of the fetuses and infants presented 
with any lung anomalies or pneumonia at the 
time of death. Clinical information on the 
fetuses and infants in Studies II and III are 
given in Table 2.
Autopsies were performed within 3 days 
after death. The lung samples were ﬁxed in 
10% neutral buffered formalin, embedded 
in parafﬁn, and stored at room temperature. 
Four-micrometer sections were stained 
with hematoxylin-eosin. After evaluation 
of the whole material, one representative 
tissue block from each case was selected for 
immunohistochemical studies.
1.3. Animals (IV)
The study protocol was approved by the 
Institutional Review Board for Animal Studies 
of Helsinki University Central Hospital, 
Helsinki, Finland. Female Wistar rats (age 8 
weeks, weight 180 g) were purchased from 
Harlan Nederland (Harlan Nederland, Horst, 
The Netherlands). After the animals were 
housed for 1 week, exposure to hyperoxia 
(>95% O
2
) or normoxia was carried out at the 
Laboratory Animal Center of Biomedicum 
Helsinki, University of Helsinki. 
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2.1. Collection and analysis for dilution of 
TAF samples (I, II)
In Study I, a total of 56 TAF samples were 
collected from 16 preterm infants during their 
ﬁrst 5 postnatal days. In Study II, 249 samples 
were collected from 32 preterm infants during 
their ﬁrst 2 postnatal weeks.  The samples 
were collected once daily by standardized 
routine tracheal lavage as previously 
described (Varsila et al. 1995). Brieﬂy, 1 mL 
of sterile isotonic saline was instilled into the 
endotracheal tube, the infant was manually 
ventilated for 3 breaths, and the trachea was 
suctioned twice, each time for 5 seconds. For 
analysis of tracheal aspirates, secretions were 
collected into a trap and transferred into tubes 
containing 500 I.U. of aprotinin (Trasylol 
®, Bayer, Leverkusen, Germany) and 5 mg 
of deferoxiamine (Desferal ®, Ciba, Basel, 
Switzerland). Aprotinin and deferoxiamine 
served to minimize oxidative and proteolytic 
artifacts. The tubes were stored at -20 ºC 
until analysis.
To eliminate the effect of dilution of 
the TAF samples, the levels of matrix 
proteinases and their inhibitors in TAF were 
related to concentrations of the secretory 
component of immunoglobulin-A IgA 
(SC), as the reference protein, with direct 
ELISA. The concentration of SC in lung 
secretions is independent of capillary leak 
and not affected by gestational or postnatal 
age during the ﬁrst month of life (Watts and 
Bruce 1995). Secretory IgA isolated from 
human colostrum served as the standard, and 
the results were standardized with the help 
of Dr. B Götze-Speer and Prof. Ch. Speer 
(University Children’s Hospital, Würzburg, 
Germany). Microtiter plates (Nunc, Roskilde, 
Denmark) were coated overnight at +4 ºC 
with 100 µL aliquots of 1:2000 diluted anti-
human secretory component (Dako, Glostrup, 
Denmark) in 50 mM sodium bicarbonate, pH 
9.5. After washing with 20 mM Tris-HCl 
buffer containing 500 mM NaCl (TBS), pH 
7.5, the plates were blocked for unspeciﬁc 
protein binding by incubation with 2% bovine 
serum albumin (BSA) in TBS and washed 
with 0.05% Tween 20 in TBS (TTBS). TAF 
samples were diluted between 1:10 to 1:500 
in diluting buffer (1% BSA in TTBS), and 
100 µL aliquots were added to the wells. After 
incubation overnight at room temperature, 
the plates were washed 3 times with TTBS. 
100 µL of peroxidase-conjugated rabbit anti-
human SC (Dako) was added to each well, 
and the plates were incubated for 4 hours at 
room temperature. After being washed with 
TTBS, the plates were developed by use of 
100 µL of substrate solution containing 8 mg 
of orthophenylenediamine (Dako) and 5 µL 
of 30% H2O2 in 12 mL water. The optical 
densities of the plates were read at 450 nm 
after 30 minutes at room temperature.
2.2. Measurement of surfactant maturity 
(I, II)
For determination of surfactant maturity, 
TAF samples were collected within 3 h 
after birth before the infants’ treatment with 
surfactant. The samples were analyzed for 
lecithin/sphingomyelin ratio (L/S ratio) and 
the presence of phosphatidyl glycerol (PG) 
by thin-layer chromathography (Hallman et 
al. 1982).
2.3. Experimental rat model of hyperoxic 
lung injury (IV)
The rats were placed in a sealed Plexiglas 
chamber (85 x 60 x 40 cm) and exposed to 
>95% oxygen for 24, 48, and 60 hours by 
administration of pure oxygen at 5 L/min. 
Oxygen concentration was monitored with 
oxymetry.  Control animals were kept in room 
2. METHODS
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air. At different exposure times, animals were 
anesthetized by intraperitoneal injections of 
ketamine (Ketalar®, Parke-Davis) 50 mg/kg 
and xylazine (Narcoxyl®, Veterinaria AG) 
10 mg/kg, and killed by cervical dislocation. 
2.3.1. Collection of lung samples
From 6 rats per group, immediately after 
decapitation, the right lung was removed and 
cut into 2 pieces. The pieces were soaked in 
isotonic saline, snap frozen in liquid nitrogen, 
and stored at      -80 °C until determination of 
myeloperoxidase activity. The left lung was 
removed, ﬁxed in 10% paraformaldehyde 
for 24 h, embedded in parafﬁn, and stored 
at room temperature for subsequent 
immunohistochemistry. 
2.3.2. Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was perfor-
med for additional 8 animals per group in 
order to avoid any potential artifact introduced 
by BAL. Immediately after the killing of each 
rat, the thoracic cavity was opened to expose 
the trachea, the trachea was cannulated, and 
the lungs were lavaged by ﬂushing with 10 
mL of sterile normal saline as 10 aliquots of 
1 mL each. Combined aliquots of BAL ﬂuid 
(BALF) were kept on ice until centrifuged at 
500 x g at 4ºC for 10 min, and the supernatant 
was stored at –20 °C for subsequent analyses. 
Total protein in the supernatant of BALF was 
measured by the method of Bradford (1976), 
and served as an indicator of increased 
vascular permeability and loss of capillary 
endothelial membrane integrity.
2.3.3. Myeloperoxidase activity in rat lung 
tissue
The lung samples were thawed, 
homogenized in phosphate-buffered saline, 
and centrifuged for 5 minutes at 16 000 x 
g, + 4 °C. Myeloperoxidase (MPO) activity 
was determined in the pellet as previously 
described (Kinsella et al. 1997). Protein 
concentration was quantiﬁed by the method 
of Bradford (1976). The results for MPO 
activity were expressed as mU/mg protein.
2.4. Zymography (II, IV)
For analysis of gelatinolytic activity by 
zymography, the polypeptides of TAF 
samples (II) and BALF samples (IV) were 
separated by 1.5-mm-thick 8 to 10% SDS-
polyacrylamide gels impregnated with 1 mg/
mL gelatin (Sigma) or with gelatin labeled 
ﬂuorescently with 2-methoxy-2,4-diphenyl-
3(2H)-furanone (Fluka, Sigma-Aldrich, 
Buchs SG, Switzerland)  as earlier described 
(Paju et al. 2001). In Study IV, the intensities 
of gelatinolytic bands were evaluated 
with a Bio-Rad Model GS-700 Imaging 
Densitometer using the Quantity-program, 
a new version of the Molecular Analyst/PC 
program (Bio-Rad Laboratories, Hercules, 
CA, USA) (Sorsa et al. 1994). Results were 
expressed as arbitrary units (AU).
2.5. Western blotting (I, II, IV)
The presence and molecular forms of MMP-
2, -8, and -9, TIMP-2 (I), and trypsin (II) in 
TAF samples from preterm infants, and of 
these MMPs and trypsin in BALF samples 
from rats (IV) were analyzed by Western 
blotting. The sources of the antibodies used 
are listed in the original publications (I, 
II, IV). After electrophoresis, the proteins 
were electrotransferred onto nitrocellulose 
membranes (Bio-Rad Laboratories, 
Richmond, CA, USA). The membranes were 
saturated with 3% gelatin or 5% milk powder 
(Valio, Helsinki, Finland).  The membranes 
ﬁrst reacted with speciﬁc primary antibodies 
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overnight at room temperature, and then with 
secondary antibodies conjugated with alkaline 
phosphatase or horseradish peroxidase for 
one hour. The proteins were visualized by 
incubation of the membranes with Nitro Blue 
Tetrazolium (Sigma) and 5-bromo-4-chloro-
3-indolyl-phosphate (Sigma) solution or 
by the enhanced chemiluminesence (ECL) 
detection system according to manufacturer’s 
instructions (Amersham Pharmacia Biotech 
Inc, NJ, USA).
In Studies I and IV, the intensity levels 
of different molecular weight forms of the 
MMPs studied (I, IV) and TIMP-2 (I) were 
evaluated with the Bio-Rad Model GS-700 
Imaging Densitometer using the Molecular 
Analyst/PC program with correction for 
background values (Sorsa et al. 1994). Results 
were expressed as arbitrary units (AU). 
2.6. Time-resolved immunoﬂuorometric 
assays (II) 
The concentrations of trypsinogen-1, 
trypsinogen-2, and TATI in TAF were 
determined by speciﬁc time-resolved 
immunoﬂuorometric assays as earlier 
described (Itkonen et al. 1990, Osman et al. 
1993). The detection limit was 0.1 µg/L for 
trypsinogen-1, 0.3 µg/L for trypsinogen-2, 
and 0.2 µg/L for TATI. The inter- and intra-
assay coefﬁcients of variation were 10 to 15% 
for trypsinogen-1, 10 to 12% for trypsinogen-
2, and 13 to 14% for TATI (Itkonen et al. 
1990, Osman et al. 1993). 
2.7. Immunohistochemical analyses (II, 
III, IV)
In autopsy lung specimens from fetuses and 
infants, the immunoreactivity of trypsin-
2 was visualized with monoclonal anti-
trypsin-2 antibody 8F7 (Itkonen et al. 1990) 
(II, III), and PAR
2
 immunoreactivity with 
polyclonal anti-PAR
2
 B5 antibody (Kong 
et al. 1997, Al-Ani et al. 1999) (III). In rat 
lung, trypsin immunoreactivity was analyzed 
with monoclonal anti-trypsin antibody MAB 
1482 (Chemicon International, Temecula, 
CA, USA), and MMP-8 immunoreactivity 
with polyclonal anti-MMP-8 antibody 
(Hanemaaijer et al. 1997) (IV).
Four-micrometer sections were 
deparafﬁnized and rehydrated. To enhance 
antigen retrieval, the sections were pretreated 
with microwave heat. Endogenous peroxidase 
was quenched by incubating the sections 
in methanol and hydrogen peroxidase. 
After application of blocking serum, the 
sections were incubated overnight at room 
temperature with the primary antibody. 
Bound antibody was visualized by the 
avidin-biotin complex immunoperoxidase 
technique (ABC) (Elite ABC kit, Vectastain, 
Vector Laboratories, Burlingame, CA, USA) 
following the manufacturer’s instructions. 
The sections were incubated with the 
biotinylated secondary antibody and the 
peroxidase-labelled avidin-biotin complex 
for 30 minutes each. Bound peroxidase was 
visualized with 3-amino-9-ethyl-carbazole 
(AEC) solution (A-5754, Sigma), and ﬁnally 
the sections were stained with hematoxylin.
For negative controls, the primary 
antibodies were replaced with neutral isotonic 
phosphate-buffered saline (II, III, IV). In 
addition, for PAR
2
, negative controls were 
performed by preabsorbing the antibody with 
the non-conjugated immunogenic peptide 
and incubating 3 hours at room temperature 
before application to the tissue. In Study 
IV, rat pancreatic tissue served as a positive 
control for trypsin immunohistochemistry, 
and rat skin specimens served as positive 
controls for MMP-8 immunohistochemistry 
(Pirila et al. 2001).
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2.7.1. Semiquantitative analysis
In Study III, the immunoreactivity of  PAR
2
, and 
in Study IV, the immunoreactivity of trypsin 
were analyzed and scored independently by 
two investigators in a blinded fashion. In 
each case, the entire section of lung tissue 
was evaluated. In Study III, PAR
2
 level was 
scored in a semiquantitative manner as 5 
levels (absent = 0, low = 1, moderate = 2, 
strong = 3, very strong = 4). Separate scores 
were given for bronchial and bronchiolar 
epithelium, alveolar epithelium, bronchial 
smooth muscle cells, vascular smooth muscle 
cells, and vascular endothelium. In Study 
IV, the immunoreactivity of trypsin was 
semiquantiﬁed according to the following 
method: absent = 0, low = 1, moderate = 
2, or strong = 3. Bronchial and bronchiolar 
epithelium, alveolar epithelium, and vascular 
smooth muscle were scored separately.
2.8. Statistical analyses
P values < 0.05 were considered statistically 
signiﬁcant.  All calculations were done 
with StatView 4.1 (Abacus Concepts Inc., 
Berkeley, CA, USA).
Studies I and II. Patient data in both 
studies are given as mean ±± SD. In Study 
I, results are expressed as mean ±± SEM, 
and in Study II as medians and ranges and 
interquartiles. The Mann-Whitney U-test 
(I, II) or Fisher’s exact test (II) was used 
to compare differences between groups. 
Logarithmic transformation of the data was 
performed for the linear regression analysis 
used for continuous variables (I, II). 
Studies III and IV. Data are expressed as 
medians, interquartiles, and 10th and 90th 
percentiles. Comparisons between groups 
were performed with the nonparametric 
multiple comparison Kruskal-Wallis test. 
Dunn’s test was used for the post hoc 
comparisons. 
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1.1. MMP-2, MMP-8, and MMP-9, and 
TIMP-2 in TAF (I)
In TAF samples from 16 preterm infants with 
respiratory distress, the presence and forms 
of MMP-2, -8, and -9, and TIMP-2 during the 
ﬁrst 5 postnatal days were characterized by 
use of Western blotting (I, Figure 1). MMP-
2 was detectable in TAF samples from all 
infants. It was detected as high molecular 
weight complexed forms, at the level of 70 
and 60 kD corresponding to latent and active 
forms of MMP-2, and as lower molecular 
weight fragmented forms (I, Figure 1). Both 
the neutrophil-derived 70- to 80-kD isoform 
of MMP-8 and the mesenchymal cell-
derived 40- to 60-kD MMP-8 occurred. Of 
the isoforms, the neutrophil-derived MMP-8 
species clearly predominated, and it appeared 
in all infants. In 13 of them, mesenchymal 
cell-derived MMP-8 was also detectable. 
Neutrophil-derived active MMP-8 appeared 
in a small number of samples, and MMP-8 
also in complexed and fragmented forms (I, 
Figure 1). MMP-9 was detectable in 13 infants, 
in complexed, 90-kD latent, and active forms 
(I, Figure 1). TIMP-2 was demonstrable as 
high molecular weight complexed forms, 
in native intact form, and 8 infants showed 
fragmented TIMP-2 (I, Figure 1). TIMP-2 
could be detected in TAF samples from all 
but one infant who died of severe respiratory 
distress at the age of 12 days.  
The levels of MMP-2, -8, and -9 in TAF 
samples were evaluated by densitometric 
scanning of the Western blots. 
RESULTS
Table 3.  Perinatal variables and levels of MMP-2, -8, and -9, and TIMP-2 (AU/SC unit) in TAF during the 
ﬁrst 5 postnatal days (Study I)
Parameter Total MMP-2 Latent MMP-8 Total MMP-9 Total TIMP-2
PMN Mes
Gestational age R = 0.37* R = 0.03 R = 0.59** R = 0.05 R = 0.46**
Birth weight R = 0.16 R = -0.18 R = 0.37* R = -0.12 R = 0.33*
PROM, present
        vs
PROM, absent
121.9 ± 44.4
         vs
71.1 ± 40.0*
26.8 ± 6.2
        vs
9.8 ± 2.3***
4.1 ± 1.9
     vs
3.4 ± 3.0
7.9 ± 1.9
     vs
1.8 ± 0.5*
8.6 ± 2.1
      vs
14.9 ± 9.2
PMN, neutrophil-derived; Mes, mesenchymal cell-derived; PROM, premature rupture of the membranes 
>  24 hours before labor 
* P < 0.05, ** P < 0.001, *** P < 0.0001
1. LUNG INJURY IN PRETERM INFANTS (I, II, III)
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MMP-2. Total MMP-2 immunoreactivity 
(complexed + latent + active + fragmented) 
in TAF during the ﬁrst 5 postnatal days 
showed a positive correlation with gestational 
age, but not with birth weight (Table 3). A 
negative correlation existed between MMP-2 
and umbilical cord artery pH and base excess 
(both R = -0.29, P < .05).
MMP-8.  During the ﬁrst 5 postnatal days, 
levels of mesenchymal-derived latent 
MMP-8 showed positive correlations with 
gestational age and birth weight (Table 3). 
In contrast, no correlations existed between 
levels of neutrophil-derived latent MMP-8 
and gestational age or birth weight (Table 3). 
Levels of neutrophil-derived latent MMP-8 
were strongly associated   
 
Table 4. Parameters of respiratory distress and levels of neutrophil-derived latent MMP-8 in TAF (Study I)
Parameter
Neutrophil-derived latent  MMP-8
(AU/SC unit)
L/S ratio R = -0.39**
Phosphatidyl glycerol (+ vs -)   7.5 ± 1.2 vs 27.5 ± 6.2**
Surfactant therapy (+ vs -) 25.4 ± 6.3 vs 10.6 ± 1.5*
Doses of surfactant R = 0.30*
Dexamethasone therapy (+ vs -) 23.0 ± 5.5 vs 16.1 ± 4.2*
Intubation >1 week (+ vs -) 22.8 ± 4.6 vs 17.2 ± 6.9*
Development of BPD (+ vs -)     27.6 ± 5.2 vs 15.1 ± 5.0***
+ vs -, levels of neutrophil-derived latent MMP-8 in infants with or without the given factor
* P < 0.05, ** P < 0.01, *** P < 0.001
with an immature surfactant proﬁle and 
severe respiratory distress; an inverse 
correlation existed with L/S ratio, and 
signiﬁcantly higher levels were demonstrated 
in infants in whom phosphatidyl glycerol was 
undetectable in surfactant analysis (Table 4). 
Levels of neutrophil-derived latent MMP-
8 were signiﬁcantly higher in infants who 
needed surfactant treatment, and these levels 
showed a positive correlation with number of 
surfactant doses given. Moreover, the levels 
of neutrophil-derived latent MMP-8 during 
the ﬁrst 5 postnatal days were associated with 
prolonged respiratory distress, as indicated 
by higher levels of the enzyme in infants 
intubated for longer than 1 week and in those 
who later were treated with dexamethasone 
to facilitate weaning from mechanical 
ventilation (Table 4). 
MMP-9. No correlations existed between 
levels of total MMP-9 immunoreactivity 
(complexed + latent + active) and gestational 
age or birth weight (Table 3). Levels of 
MMP-9 during the study period showed no 
association with surfactant treatment and 
no correlation with duration of mechanical 
ventilation.
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TIMP-2. During the ﬁrst 5 postnatal days, 
a positive correlation existed between levels 
of total TIMP-2 in TAF (complexed + native 
+ fragmented) and gestational age and birth 
weight (Table 3). The levels showed positive 
correlations with levels of total MMP-
2 and total MMP-9 (R = 0.68, R = 0.64, 
respectively; both P < 0.0001). In addition, 
a positive correlation existed between the 
levels of TIMP-2 and mesenchymal cell-
derived latent MMP-8 (R = 0.61, P = 0.003), 
but no correlation existed with neutrophil-
derived latent MMP-8 (R = 0.03, P = 0.8). 
TIMP-2 was lower in infants with more 
severe respiratory distress, as indicated by 
lower levels in infants with an initial arterial-
to-alveolar oxygen tension ratio (aAPO2) < 
0.22 (I, Figure 2A), in infants who needed 
treatment with surfactant, and in those 
requiring mechanical ventilation for more 
than one week (I, Figure 2B).
Association with premature rupture of 
membranes (PROM). In premature infants 
born to mothers with PROM, TAF levels of 
total MMP-2 and MMP-9, as well as those 
of neutrophil-derived latent MMP-8, were 
signiﬁcantly higher than in other infants. In 
contrast, no signiﬁcant difference existed in 
the levels of mesenchymal cell-derived latent 
MMP-8 and TIMP-2 (Table 3).
1.2. Trypsin and tumor-associated trypsin 
inhibitor (TATI) in TAF (II)
By use of gelatin zymography and Western 
blotting, two major immunoreactive species 
of trypsin was identiﬁed: trypsin-1 and 
trypsin-2 with molecular weights of 25 
and 28 kD. In addition, 40-kD to 100-kD 
relatively faint complexed forms of trypsin 
were present (II, Figure 1). 
The concentrations of trypsinogen-1 and 
trypsinogen-2, and TATI in TAF determined 
by speciﬁc immunoﬂuorometric assays were 
above the detection limit of the assay in 86%, 
96%, and 97% of the samples, respectively. 
The median (range) concentration of 
trypsinogen-1 was 1.6 (0.0-95) ng/SC unit 
during week 1, and 0.9 (0.0-17) ng/SC unit 
during week 2. During week 1, the median 
concentration of trypsinogen-2 was 14.5 
(0.0-235) ng/SC unit, and during week 2 was 
17.3 (0.0-267) ng/SC unit. During weeks 1 
and 2, positive correlations appeared between 
the concentrations of trypsinogen-1 and 
trypsinogen-2 (R = 0.49 and R = 0.45; both P 
<0.0001). The median concentration of TATI 
during week 1 was 35.1 (3.9-926) ng/SC unit, 
and 21.0 (2.6-342) ng/SC unit during week 2. 
During weeks 1 and 2, positive correlations 
appeared between  concentrations of TATI 
and trypsinogen-1 (R = 0.41, P < 0.001; R = 
0.44, P < 0.0001), and between those of TATI 
and trypsinogen-2 (R = 0.34, P < 0.01; R = 
0.50, P < 0.0001).
Trypsinogen-1. During week 1, trypsinogen-
1 showed a positive correlation with 
gestational age (R = 0.36, P < 0.001). 
Its concentration correlated neither with 
proteinuric pre-eclampsia, antenatal 
glucocorticoid treatment, birth weight, 
severity of acute respiratory distress, nor 
duration of mechanical ventilation. 
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Table 5. Parameters of respiratory distress and concentrations of trypsinogen-2 in TAF during weeks 1 
and 2 (Study II)
Parameter
Trypsinogen-2 (ng/SC unit)
Week 1 Week 2
L/S ratio 1 R = -0.36** R = -0.66***
PG in TAF  (+ vs -) 2 5.5 (0.4-25) vs 19.4 (0-235)*** 1.8 (0.5-10.5) vs 23.0 (0-193)***
aAPO2 ≤ 0.22 (+ vs -) 
3 19.1 (0.4-235) vs 11.0 (0-118) 27.2 (0.5-266) vs 9.5 (0-66)***
Surfactant therapy (+ vs -) 20.9 (0-235) vs 10.7 (0-118)* 23.0 (0-266) vs 8.0 (0-66)**
Dexamethasone (+ vs -) 19.8 (0-235) vs 8.6 (0-158)** 14.3 (0-266) vs  28.3 (0-38)
Duration of intubation (d) R = 0.30** R = 0.1
BPD (+ vs -) 22.0 (0.4-235) vs 10.0 (0-114)*** 25.5 (0.5-266) vs 9.0 (0-66)***
Values presented as median (range).
+ vs -, concentrations of trypsinogen-2 in infants with or without the given factor
1 Lecithin/sphingomyelin ratio and 2 phosphatidyl glycerol, measured from TAF sample obtained within 3 
hours after birth; 3 Arterial to alveolar oxygen tension ratio
* P < 0.05, **P < 0.01, ***P < 0.0005
Trypsinogen-2. During week 1, the 
concentration of trypsinogen-2 showed a 
weak negative correlation with birth weight (R 
= -0.26, P = 0.005), but no correlation existed 
between the concentration of trypsinogen-
2 and gestational age. No association was 
detectable between the concentration of 
trypsinogen-2 and antenatal glucocorticoid 
treatment. Trypsinogen-2 was signiﬁcantly 
higher in preterm infants born to mothers with 
proteinuric pre-eclampsia, than in those whose 
mothers had chorioamnionitis or PROM, or 
in preterm infants without these antenatal 
complications (II, Figure 2). A negative 
correlation appeared between trypsinogen-
2 concentration and surfactant maturity, as 
measured by lecithin/sphingomyelin ratio 
(L/S-ratio), and the presence of phosphatidyl 
glycerol in TAF (Table 5). Trypsinogen-2 
was higher in preterm infants with a more 
severe acute respiratory distress, as indicated 
by higher concentrations of trypsinogen-
2 in preterm infants with an initial aAPO2 
≤ 0.22, and in those who needed treatment 
with surfactant (Table 5). During week 
1, higher concentrations of trypsinogen-
2 were detectable in preterm infants who, 
to facilitate weaning from mechanical 
ventilation, received dexamethasone (age at 
start of treatment: mean ± SD: 13 ± 7 days; 
range: 3-33 days). In addition, concentration 
of trypsinogen-2 during week 1 showed 
a positive correlation with duration of 
mechanical ventilation (Table 5). 
TATI. Positive correlations appeared between 
birth weight and TATI concentrations during 
weeks 1 and 2 (R = 0.27, P = 0.008; R= 
0.38, P = 0.0002). No correlation existed 
between TATI and proteinuric pre-eclampsia 
or severity of acute respiratory distress. 
However, concentrations of TATI during 
week 1 were lower in preterm infants who 
needed mechanical ventilation for more than 
one week: median 27.2 (range 3.9 - 926) ng/
SC unit vs. 61.8 (range 18.4 - 534) ng/SC-
unit, P < 0.0001.
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1.3. Matrix proteinases and their inhibitors 
in TAF, and development of BPD (I, II), 
MMP-2
MMP-8, MMP-9, and TIMP-2 (I). During 
the ﬁrst 5 postnatal days, levels of neutrophil-
derived latent MMP-8 were signiﬁcantly 
higher in TAF samples from preterm infants 
who subsequently developed BPD than 
in those who survived without it (Table 4, 
Figure 3 in Study I). No associations existed 
between development of BPD and levels of 
mesenchymal cell-derived MMP-8, MMP-2, 
MMP-9, or TIMP-2. When all patients with 
an unfavorable respiratory outcome (6 infants 
who subsequently developed BPD and 2 
infants who died from severe respiratory 
distress on days 12 and 24) were combined, 
in this group levels of TIMP-2 in TAF were 
signiﬁcantly lower than in the group in which 
respiratory distress resolved (P < 0.05). 
Trypsinogen-1, trypsinogen-2, and TATI 
(II). Those preterm infants who subsequently 
developed BPD had signiﬁcantly higher 
trypsinogen-2 in TAF during days 5 to 10 than 
did those who survived without it (II, Figure 
3). In addition, during weeks 1 and 2, the 
ratio of trypsinogen-2 to TATI was higher in 
preterm infants who subsequently developed 
BPD than in those surviving without it (II, 
Figure 4). No differences in trypsinogen-1 
concentrations were detectable between the 
two groups.
1.4. Immunolocalization of trypsin-2 and 
PAR
2
 in human lung (II, III)
1.4.1 Trypsin-2 and PAR
2
 during the peri-
natal period
Trypsin-2. In lung tissue from the 
total 12 fetuses studied by trypsin-2 
immunohistochemistry, faint positive 
immunostaining was detectable in bronchial 
and bronchiolar epithelial cells in 5, whereas 
samples from 7 fetuses were totally negative 
(II, Figure 5A; III). Similarly, bronchial and 
bronchiolar epithelium was weakly positive 
in 3 of the 5 newborn infants (gestational 
ages 22.4 to 33.0 weeks) who had died within 
1 day after delivery without histologic signs 
of RDS (III). Faint positive staining in the 
bronchial and bronchiolar epithelium was 
also demonstrable in lung sections from all 
of the 5 term infants with normal histology 
who had died at 12 hours to 3 days. In one of 
them, positive staining was also detectable in 
alveolar type II-like pneumocytes (II, Figure 
5F).
PAR
2
. Positive immunostaining for PAR
2
 
was scored semiquantitatively, with separate 
scores given for bronchial and bronchiolar 
epithelium, alveolar epithelium, bronchial 
smooth muscle, vascular smooth muscle, and 
vascular endothelium (III, Figure 1).
 In samples from all fetuses and infants, 
immunostaining for PAR
2
 was detected in 
bronchial and bronchiolar epithelium as well 
as in alveolar epithelium.  In the 10 fetuses 
studied, the level of PAR
2
 immunoreactivity 
in bronchial and bronchiolar epithelium was 
low or moderate, although in one (gestational 
age 14 weeks), immunoreactivity was strong 
(III, Figures 1A and 2A). In cuboidal lining 
cells of the prospective pulmonary acini, 
immunoreactivity was moderate or strong 
(III, Figures 1B and 2B). The endothelium 
and the bronchial and vascular smooth 
muscle cells were negative, or showed only 
a low level of immunoreactivity (III, Figures 
1C-E and 2A). In newborn infants who had 
died without lung disorders within 1 day after 
delivery, expression of PAR
2
 in the cell types 
studied was predominantly low (III, Figures 
1 and 3A). 
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1.4.2. Immunolocalization of trypsin-2 and 
PAR
2
 in acute and chronic lung injury in 
preterm infants
Trypsin-2. In preterm infants who had died 
as a result of RDS at the age of 0 to 3 days, 
the lung sections were mainly negative in 
trypsin-2 immunostaining. Of the total of 
9 preterm infants with RDS, bronchial and 
bronchiolar epithelium as well as hyaline 
membranes showed weak positive staining in 
5 (II, Figure 5B; III). In contrast, in preterm 
infants who had died as a result of prolonged 
RDS at the age of 8 to 16 days, bronchial and 
bronchiolar epithelium was predominantly 
strongly positive. In addition, strong positive 
staining was detectable in type II-like 
pneumocytes lining walls of the airspaces, 
and of the 7 infants, positive staining was 
apparent also in vascular endothelial cells 
in 2 (II, Figure 5D; III, Figures 4B and 
4C). In infants who had died of BPD (age at 
death 75 to 306 days), positive staining that 
ranged from low to strong was detectable 
in bronchial and bronchiolar epithelium, as 
well as in bronchial metaplastic stratiﬁed 
squamous epithelium, while the alveolar 
epithelium was mainly negative (II, Figure 
5E; III, Figure 4F). 
PAR
2
. In preterm infants who died of acute 
RDS at the age of 0 to 2 days, a moderate 
level of PAR
2
 immunoreactivity was evident 
in bronchial and bronchiolar epithelium, 
whereas of the 8 preterm infants studied, 
the level was low in alveolar epithelium in 4 
(III, Figures 1A, 1B and 3B). No signiﬁcant 
difference was detected in the level of PAR
2
 
immunoreactivity between preterm infants 
who died as a result of acute RDS and 
newborn infants (gestational ages 22.4 to 33.0 
weeks) without histologic signs of RDS.
In preterm infants who died as a result of 
prolonged RDS, the level of PAR
2
 expression 
in bronchial and bronchiolar epithelium ranged 
from moderate to very strong (III, Figures 
1A and 3C), and in alveolar epithelium, the 
level was strong in 5 of 7 preterm infants 
(III, Figures 1A and 3D). When compared 
with newborn controls, the level of PAR
2
 
immunoreactivity in infants with prolonged 
RDS was signiﬁcantly higher in bronchial 
and bronchiolar epithelium, in alveolar 
epithelium, and in bronchial and vascular 
smooth muscle (III, Figure 1). In addition, the 
level of PAR
2 
in vascular endothelium tended 
to be higher than in newborn controls (P = 
0.07). In all infants who died of prolonged 
RDS, marked expression of PAR
2
 was also 
apparent in spindle-shaped cells of thickened 
alveolar walls and in ﬁbrotic foci (III, 
Figure 3C). The cells showed strong positive 
staining in immunohistochemical analysis 
for α-smooth muscle actin, thus obviously 
representing lung myoﬁbroblasts. 
In lung specimens from preterm infants 
who had died of BPD, the level of PAR
2
 
immunoreactivity was strongest in bronchial 
and bronchiolar epithelium (III, Figure 1). 
In these samples, PAR
2
 immunoreactivity 
was signiﬁcantly higher in bronchial and 
bronchiolar epithelium and also in bronchial 
smooth muscle than in samples from newborn 
infants without lung disorders (III, Figure 1). 
As in infants who had died of prolonged RDS, 
in all infants with BPD, marked expression of 
PAR
2
 was detectable in the α-smooth muscle 
actin-positive myoﬁbroblasts of thickened 
and ﬁbrotic alveolar walls (III, Figures 3E 
and 3F). In addition, PAR
2
 expression was 
visible in alveolar macrophages (III, Figure 
3E).
Co-localization of trypsin-2 with PAR
2
 in 
lung tissue. In preterm infants who had died 
as a result of prolonged RDS, the expression 
of trypsin-2 was co-localized with PAR
2
 in 
bronchial and bronchiolar epithelium and 
in type-II-like pneumocytes lining alveolar 
walls (III, Figures 4A and 4B). In addition, 
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in 2 of these infants (N = 7), the vascular 
endothelium showed strong immunoreactivity 
to both trypsin-2 and PAR
2
 (III, Figures 4C 
and 4D). In preterm infants who had died of 
analysis of BALF samples with anti-MMP-
8 antibody revealed both neutrophil-derived 
80-kD and mesenchymal cell-derived 60-kD 
MMP-8 species, of which the latter clearly 
predominated.  No MMP-8 immunoreactivity 
was visible in BALF samples from controls or 
from rats exposed to hyperoxia for 24 hours 
(IV, Figure 2C). Densitometric analysis 
showed that the levels of trypsin and MMP-2 
were signiﬁcantly increased by 48 hours of 
hyperoxia (IV, Figures 3A, 3B). At 60 hours, 
the levels of these enzymes were further 
increased, and signiﬁcant increases were 
also detectable in the levels of MMP-9 (IV, 
Figure 3) as well as both neutrophil-derived 
and mesenchymal cell-derived MMP-8 (IV, 
Figure 4).
2.2. Immunolocalization of trypsin and 
MMP-8 in rat lung 
Trypsin. In controls rats exposed to room air, 
weak expression of trypsin was detectable 
in the bronchial and bronchiolar epithelial 
cells, whereas the alveolar epithelium 
was predominantly negative (IV, Figure 
5A). In rats exposed to hyperoxia for 24 
hours, a tendency for increased trypsin 
immunoreactivity appeared in the bronchial 
and bronchiolar epithelium when compared 
with normoxia controls (IV, Figures 5B 
and 6B). At 48 and 60 hours of hyperoxia, 
2. EXPERIMENTAL HYPEROXIC LUNG INJURY IN THE RAT (IV)
BPD, trypsin-2 co-localized with PAR
2
 in 
bronchial and bronchiolar epithelium (III, 
Figures 4E and 4F).
Exposure of rats to >95% O
2
 caused no evident 
signs of respiratory distress or macroanatomic 
changes until 60 hours of exposure, at which 
point pleural effusions were visible upon 
opening of the thoracic cavity, and the lungs 
appeared hemorrhagic and consolidated. The 
concentration of protein in bronchoalveolar 
lavage ﬂuid (BALF) and myeloperoxidase 
(MPO) activity in lung tissue were not 
increased until at 48 hours (IV, Figure 1). At 
60 hours, a 10-fold increase in BALF protein 
was detected compared with BALF from 
control animals exposed to room air (IV, 
Figure 1A). 
2.1. Characterization of MMP-2, -8, and
-9, and trypsin in BALF 
At 48 hours of exposure, three gelatinolytic 
proteinases of molecular weight 28, 68, 
and 90 kD were clearly detected in gelatin 
zymograms, and the gelatinolytic activity 
was further increased at 60 hours of exposure 
(IV, Figure 2A).  In contrast, almost no 
gelatinolytic activity was detectable in BALF 
samples from controls or from rats exposed 
to hyperoxia for 24 hours (IV, Figure 2A). 
By use of Western blotting, the 28-kD species 
was identiﬁed as trypsin (IV, Figure 2B), and 
the 68-kD and 90-kD species as latent forms 
of MMP-2 and MMP–9, respectively. At 48 
hours and 60 hours of exposure, Western blot 
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marked expression of trypsin appeared in the 
alveolar epithelium, while in the bronchial 
and bronchiolar epithelium the expression 
level remained low (IV, Figures 5C and 
5D). In the alveolar epithelium, the level of 
trypsin immunoreactivity was signiﬁcantly 
increased in rats exposed to hyperoxia for 48 
and 60 hours when compared with normoxia 
controls (P < 0.05 and P < 0.005, respectively) 
(IV, Figure 6A). In 4 rats per exposure group 
(N = 6 in group), moderate to strong trypsin 
immunoreactivity was visible in vascular 
smooth muscle of the large arteries after 
exposure to hyperoxia for 48 and 60 hours.  In 
addition, trypsin immunoreactivity appeared 
in the hyaline membranes and occasionally 
in intra-alveolar macrophages mainly seen at 
60 hours of hyperoxia.
MMP-8. In sections of rat lung, almost 
no immunoreactivity to MMP-8 was 
detectable until 48 hours of hyperoxia, at 
which time point positive cells with a large 
cytoplasm, obviously representing recruited 
macrophages, could be demonstrable in the 
edematous perivascular space (IV, Figures 
7A-7C). After 60 hours of hyperoxia, a great 
number of macrophages strongly positive 
for MMP-8 appeared in the alveoli as well 
as in the interstitium (IV, Figures 7D and 
7E). Although expression of MMP-8 was 
predominantly localized macrophages, it was 
also visible in intravascular and perivascular 
neutrophils at 48 hours of hyperoxia, and, in 
addition, at 60 hours in neutrophils located in 
the interstitial and intra-alveolar space (IV, 
Figure 7D and 7F). 
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Lung ECM provides a highly structurized 
reservoir of various growth factors and 
cytokines, and it inﬂuences the proliferation, 
migration, differentiation, and functioning 
of lung epithelial and mesenchymal cells 
(Dunsmore and Rannels 1996). Therefore, 
remodeling of the ECM and BM, a process in 
which MMPs play key roles, is an important 
part of harmonious pulmonary development 
We characterized the presence, molecular 
forms, and species of MMP-2 (gelatinase 
A), MMP-9 (gelatinase B), and MMP-8 
(collagenase-2), as well as their speciﬁc 
inhibitor TIMP-2 in TAF samples from 
preterm infants with respiratory distress 
during the early postnatal period and showed 
that MMP-8 in TAF consisted of both 70-
80 kD neutrophil-derived and 40-60 kD 
mesenchymal cell-derived isoforms of MMP-
8. In line with this, both isoforms of MMP-
8 also exist in BALF samples from adult 
patients with asthma and from those with 
bronchiectasis (Prikk et al. 2001a, 2002). 
Of the MMP-8 isoforms, the neutrophil-
derived species predominated in preterm 
infants. Although neutrophil-derived MMP-8 
appeared mostly in its non-converted latent 
80-kD form, this form may represent an 
DISCUSSION
(Roth-Kleiner and Post 2005, Ryu et al. 
2005). During lung inﬂammation, excessive 
production and release of matrix proteinases 
including MMPs and matrix serine 
proteinases cause dysregulated degradation 
of ECM and BM, which in the preterm lung 
may subsequently lead to abnormal repair and 
aberrant lung development, and eventually 
result in BPD (Chua et al. 2005).
1. MMP-2, -8, AND -9, AND TIMP-2 IN LUNG INJURY IN PRETERM INFANTS
oxidatively activated form of MMP-8 in vivo. 
Activation of MMP-8 in vitro by reactive 
oxygen species does not necessarily involve 
any change in molecular weight (Saari et al. 
1990), and the lungs of preterm infants with 
RDS and of those subsequently developing 
BPD show increased oxidative stress (Varsila 
et al. 1995). 
We found neutrophil-derived latent MMP-
8 to be strongly associated with severity 
of acute respiratory distress. In addition, 
during the ﬁrst ﬁve postnatal days it was 
higher in those preterm infants in whom 
respiratory distress prolonged, i.e. who 
were mechanically ventilated for more than 
one week and who required treatment with 
dexamethasone. Moreover, those preterm 
infants who subsequently developed BPD 
showed higher TAF levels of neutrophil-
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derived latent MMP-8 than did those who 
survived without it. This is consistent with 
the ﬁnding of Sweet et al. (2001) who, in 
BALF samples from preterm infants who 
later developed BPD, showed higher levels 
of MMP-8 during the ﬁrst six postnatal 
days. In accordance with these ﬁndings, 
the concentrations and activation levels of 
MMP-8 are increased in BALF from adults 
with chronic tissue-destructive lung diseases 
including asthma and bronchiectasis (Prikk 
et al. 2001a, 2002). 
In the preterm lung, MMP-8 can induce 
tissue injury through its capacity to degrade 
type I collagen, the major structural protein 
of the ECM. In addition, it can degrade and 
inactivate α
1
-antitrypsin, thereby promoting 
the activities of serine proteinases trypsin 
and elastase (Owen et al. 2004). Recent 
studies in MMP-8 knockout animals have, 
however, shown that MMP-8 may also have 
anti-inﬂammatory effects, including a role 
in the regulation of neutrophil apoptosis 
during allergen-induced airway inﬂammation 
(Gueders et al. 2005). 
In contrast to neutrophil-derived MMP-8, 
the levels of mesenchymal cell-derived MMP-
8 during the ﬁrst 5 postnatal days showed 
positive correlations with gestational age and 
birth weight. In this respect, mesenchymal 
cell-derived MMP-8 resembled MMP-2, 
which also correlated with gestational age, 
and appeared to be expressed constitutively. 
These results suggest that these two may 
be involved in the remodeling of ECM 
associated with lung growth. In experimental 
animals, MMP-2 is involved in late fetal 
lung development and postnatal lung growth 
(Arden et al. 1993, Fukuda et al. 2000). In 
general, MMP-2 is produced constitutively, 
and during lung development is mainly 
expressed by mesenchymal cells such as 
vascular endothelial and smooth muscle cells 
(Kheradmand et al. 2002, Masumoto et al. 
2005). Although we found no association 
between levels of MMP-2 during the ﬁrst 
ﬁve postnatal days and the subsequent 
development of BPD, later studies by Danan 
et al. (2002) and Ekekezie et al. (2004) 
have shown lower levels of MMP-2 early 
postnatally in tracheal aspirates from preterm 
infants subsequently developing BPD. In the 
study of Danan et al., the difference in MMP-
2 levels between groups was detectable in 
TAF samples collected within six hours after 
birth, but not on day three or ﬁve. Similarly, 
Ekekezie et al. detected an association 
between low MMP-2 and BPD in samples 
collected on days zero to three. 
We could show no association between 
levels of MMP-9 in TAF during the ﬁrst 5 
postnatal days and severity of respiratory 
distress or subsequent development of BPD. 
This is consistent with the results of Ekekezie 
et al. (2004) who found no difference in TAF 
levels of MMP-9 during the ﬁrst two postnatal 
weeks between preterm infants developing 
BPD or not. They, however, detected lower 
levels of TIMP-1 and a higher ratio of MMP-
9 to TIMP-1 during the ﬁrst two postnatal 
weeks in preterm infants who subsequently 
developed BPD than in those who recovered 
from RDS. 
Premature rupture of the membranes 
(PROM) is associated with intra-amnionic 
inﬂammation, a risk factor for subsequent 
development of BPD (Watterberg et al. 
1996, Jobe 2003). These preterm infants 
may initially have no RDS or only mild 
respiratory disease, but after a few days or 
weeks show progressive deterioration of 
lung function and increased ventilatory and 
oxygen requirements (Bancalari et al. 2003).
Our study showed higher levels of 
neutrophil-derived MMP-8, but also higher 
levels of MMP-2 and MMP-9 in infants born 
to mothers with PROM than in infants born 
to mothers without this complication. In 
contrast, no difference was detectable in the 
levels of TIMP-2. The increase in the levels 
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of several pulmonary MMPs insufﬁciently 
counteracted by TIMP-2 during the early 
postnatal period may be involved in the 
increased risk for development of BPD in 
these infants. Our results are in agreement 
with those of Curley et al. (2003, 2004), who 
have demonstrated higher levels of MMP-8 
and MMP-9, but not TIMP-1, in BALF from 
ventilated preterm infants from pregnancies 
complicated by chorioamnionitis.
We detected TIMP-2 predominantly as 
high molecular weight complexed forms 
reﬂecting TIMP-2-species bound to MMPs, 
but free native and fragmented lower 
molecular weight species also occurred. 
Fragmented TIMP-2 appeared in 8 of our 16 
preterm infants. During the ﬁrst 5 postnatal 
days, the levels of total TIMP-2 were lower 
We observed higher pulmonary concen-
trations of trypsinogen-2 in preterm 
infants with more severe acute respiratory 
distress. Moreover, the concentrations 
were higher during days 5 to 10 in those 
subsequently developing BPD than in those 
who survived without it.  In addition, those 
infants developing BPD had a higher ratio 
of trypsinogen-2 to TATI during week 1 
and week 2. No differences occurred in the 
concentrations of trypsinogen-1 between 
these groups. 
In preterm infants who had died of acute 
RDS on days 0 to 3, immunohistochemical 
analysis for trypsin-2 showed weak positive 
staining in bronchial and bronchiolar 
epithelial cells in 5 of the 9 studied infants, 
whereas the other 4 showed no trypsin-2. In 
contrast, in those who died at age 8 to 16 days, 
the bronchial and bronchiolar epithelium 
showed intense expression of trypsin-2, and 
in infants with more severe acute respiratory 
distress, and in those who later had a poor 
respiratory outcome (development of BPD 
or death from prolonged severe respiratory 
distress). It is noteworthy that these clinical 
conditions were also associated with higher 
levels of MMP-8 in TAF. These results 
suggest that an imbalance between MMP-
8 and its endogenous inhibitor TIMP-2 
in the lungs of preterm infants may play a 
role in the acute lung injury, and thereby 
may inﬂuence its outcome. Our ﬁnding of 
an association between low TIMP-2 and 
poor respiratory outcome is in agreement 
with that of Ekekezie et al. (2004) who in 
preterm infants subsequently developing 
BPD showed low TIMP-2 early postnatally 
(Ekekezie et al. 2004). 
2. TRYPSIN-1, AND -2, AND TATI IN LUNG INJURY IN PRETERM INFANTS
marked positive staining was also evident in 
type II-like pneumocytes lining the walls of 
the airspaces. 
In the lungs of infants dying of 
nonpulmonary causes, trypsin-2 was 
expressed at low levels in bronchial and 
bronchiolar epithelial cells, in line with the 
ﬁndings of studies showing expression of 
trypsin in normal adult human bronchial 
epithelium, and this supports the hypothesis 
that trypsin may also participate in normal 
cellular functions (Koshikawa et al. 1998, 
Cocks et al. 1999).
Little is known about the role of trypsin 
in the lung. If dysregulated, trypsin may 
cause pulmonary tissue destruction through 
direct degradation of ECM and BM proteins 
(Koivunen et al. 1991, Koshikawa et al. 
1992, Moilanen et al. 2003, Stenman et al. 
2005) as well as through activation of various 
proMMPs, including MMP-1, -3, -8, -9, and 
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-13 (Sorsa et al. 1997, Moilanen et al. 2003). 
We observed activation of the MMP cascade 
in the lungs of preterm infants with respiratory 
distress (I). During the inﬂammatory reaction, 
α
1
-antitrypsin is inactivated both oxidatively 
by reactive oxygen species released from 
inﬂammatory cells (Carp and Janoff 1980) and 
proteolytically by several MMPs, including 
MMP-8 and -9 (Liu et al. 2000, Owen et al. 
2004). Thus, MMP-8 and trypsin-2 may act 
synergistically by potentiating each others’ 
activity during development of lung injury in 
preterm infants. 
The potential role of pulmonary trypsin in 
the development of BPD raises the possibility 
of preventing BPD by use of exogenous 
proteinase inhibitors; α
1
-antitrypsin protects 
neonatal rats from the toxic effects of 
oxygen on pulmonary parenchymal and 
vascular development (Koppel et al. 1994). 
Furthermore, in a randomized, controlled 
trial, prophylactic administration of α
1
-
antitrypsin intravenously to preterm infants 
with RDS reduced the incidence of pulmonary 
hemorrhage and the use of inhaled steroids 
and bronchodilators, although it failed to 
reduce the risk for BPD at 36 gestational 
weeks (Stiskal et al. 1998). On the basis of our 
results, the favorable effects of α
1
-antitrypsin 
may partially be explained by inhibition of 
pulmonary trypsin.
2.1. PAR
2
 in lung injury in preterm 
infants
Extrapancreatic trypsin-2 potently activates 
PAR
2 
(Alm et al. 2000). We observed that in 
preterm infants who had died of prolonged 
RDS, trypsin-2 was co-localized with PAR
2
 
in bronchial and alveolar epithelium. PAR
2
 
was highly expressed in the bronchial and 
bronchiolar epithelium of preterm infants 
who had died of prolonged RDS or BPD, and 
the expression was signiﬁcantly stronger in 
comparison with newborn infants who had 
died of nonpulmonary reasons. In addition, 
the level of PAR
2
 immunoreactivity in 
alveolar epithelium of preterm infants with 
prolonged RDS was signiﬁcantly higher than 
in newborn infants. 
Interestingly, we detected strong expression 
of PAR
2
 in α-smooth muscle actin-positive 
myoﬁbroblasts of the thickened and ﬁbrotic 
alveolar walls in preterm infants who died of 
prolonged RDS or BPD. Trypsin is capable 
of inducing lung ﬁbroblast proliferation 
via activation of PAR
2
 (Akers et al. 2000). 
Myoﬁbroblasts are derived from activated 
ﬁbroblasts, and play an important role in 
tissue remodeling following acute lung 
injury. In preterm infants with acute lung 
injury, myoﬁbroblasts increase in number 
and form bundles encircling terminal air 
spaces during the early postnatal period (Toti 
et al. 1997). Our ﬁndings of higher PAR
2
 in 
myoﬁbroblasts suggest that PAR
2
 may be 
involved in the ﬁbroproliferation associated 
with development of BPD.
PAR
2
 was also visualized in bronchial 
and vascular smooth muscle, vascular 
endothelium, and alveolar macrophages, in 
accord with studies on the localization of 
PAR
2
 in the adult human lung (D’Andrea et 
al. 1998, Akers et al. 2000, Ricciardolo et al. 
2000, Knight et al. 2001, Asokananthan et al. 
2002, Steinhoff et al. 2005). 
In the respiratory epithelium, activation of 
PAR
2
 stimulates the release of inﬂammatory 
mediators such as IL-6, IL-8, and matrix 
metalloproteinase-9, suggesting an important 
role for PAR
2
 in lung inﬂammation and 
tissue remodeling (Vliagoftis et al. 2000, 
Asokananthan et al. 2002).   In preterm infants 
with respiratory distress, the development 
of BPD is characterized by a persistent 
inﬂammatory pulmonary reaction associated 
with epithelial cell damage and increased 
alveocapillary permeability (Merritt et al. 
1983, Groneck et al. 1994, Watterberg et al. 
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1996). In addition to alveolar macrophages, 
vascular endothelium and respiratory 
epithelium play an important role in the 
production of the pro-inﬂammatory cytokines 
(Kotecha et al. 1996). Up-regulated PAR
2
 in 
the injured preterm lung may be involved in 
this inﬂammatory process. 
3. MMP-2, -8, AND -9, AND TRYPSIN IN HYPEROXIC LUNG INJURY IN THE RAT
Hyperoxic lung injury is characterized by 
damage to the alveolar–capillary barrier with 
subsequent increased pulmonary vascular 
permeability, progressive inﬂammation, and 
pulmonary edema (Crapo et al. 1980). The 
early stages of oxygen toxicity begin with an 
initiation phase, occurring within the ﬁrst 40 
hours of hyperoxia exposure, in which few 
demonstrable morphologic changes exist 
(Crapo et al. 1980). We detected in the rat a 
rapid increase in the pulmonary expression 
of trypsin during the early development 
of hyperoxic lung injury. After 48 hours of 
exposure to >95% oxygen, strong expression 
of trypsin occurred in the alveolar epithelium, 
which–in contrast–showed almost no 
immunoreactivity for trypsin under normoxic 
conditions. 
In addition to trypsin, zymography of 
BALF samples from rats exposed to 48 and 
60 hours of hyperoxia demonstrated the up-
regulation of two other gelatinolytic enzymes 
identiﬁed as MMP-2 and -9. Similarly to 
trypsin, MMP-2 and MMP-9 can efﬁciently 
degrade BM components (Sorsa et al. 1997, 
Chakrabarti and Patel 2005).  The marked 
up-regulation of trypsin, MMP-2, and -9 
in BALF coincided with an increase in the 
alveolar-capillary permeability, as indicated 
by an increased protein concentration in 
BALF, suggesting a role in the degradation 
of alveolar-capillary BM associated with 
the development of hyperoxic lung injury. 
In accordance with our results, increased 
expression of pulmonary MMP-2 and -9 has 
been shown in rats exposed to 100% oxygen 
for 60 hours (Pardo et al. 1996). 
Although trypsin in vitro efﬁciently 
activates latent forms of MMPs, including 
MMP-8 and -9 by removing the propeptide, 
most of the MMPs-2, -8, and -9 detected in 
BALF samples were as demonstrated by 
Western blotting, in their non-converted 
proforms.  These ﬁndings are in line with 
those of Study I, in which we found that 
especially MMP-8, but also MMP-9 was 
mainly detectable in latent form in TAF 
samples from preterm infants. Some of the 
non-converted forms may, however, represent 
oxidatively activated forms of these MMPs 
in vivo, since in vitro oxidative activation of 
MMP-8 or -9 does not necessarily involve 
changes in their molecular sizes (Westerlund 
et al. 1996). 
A rat model of experimental pancreatitis-
associated lung injury has shown that infusion 
of trypsin or trypsinogen causes acute dose-
dependent pulmonary injury characterized 
by perivascular edema and hemorrhage 
(Hartwig et al. 1999). These authors further 
showed that this lung injury is neutrophil-
dependent, and is possibly mediated by the 
ability of trypsin to up-regulate pulmonary 
intercellular adhesion molecule-1, a key 
vascular endothelial adhesion molecule 
necessary for transport of leukocytes from 
the intravascular space into inﬂamed tissues 
(Hartwig et al. 2004). 
It is noteworthy that the increased trypsin 
in the alveolar epithelium may also play a 
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protective role in the development of lung 
injury. In the injured lung, active transepithelial 
transport of Na+ limits alveolar edema. The 
effect of serine proteinases, including trypsin, 
on ion transport has recently been studied by 
Swystun et al. (2005), who demonstrated in 
vitro that apical trypsin enhanced both ion 
transport across rat alveolar type II cells 
and paracellular resistance, indicating that 
trypsin may play an important role in the 
clearance of alveolar ﬂuid. Moreover, in 
ﬂuid-ﬁlled lungs in a rat model, inhibition of 
trypsin activity by intratracheal instillation 
of soybean trypsin inhibitor or α
1
-antitrypsin 
decreases the amiloride-sensitive    lung-ﬂuid 
clearance, and this effect is partially restored 
by instillation of trypsin (Swystun et al. 
2005). 
We observed a marked up-regulation 
of MMP-8 in the rat lung after 48 hours of 
exposure to hyperoxia. MMP-8 has been 
regarded solely as a neutrophil-speciﬁc 
MMP or collagenase-2 stored in granules 
and released upon activation (Weiss 1989). 
However, certain activated mesenchymal 
cells also express MMP-8 (Hanemaaijer 
et al. 1997). In BALF, we detected both 
neutrophil-derived 80-kD MMP-8 and 60-kD 
mesenchymal cell-derived MMP-8 species, 
of which the latter clearly predominated. This 
is in contrast with our previous ﬁndings of 
MMP-8 in TAF samples from preterm infants, 
in which the neutrophil-derived MMP-8 was 
the main isoform of the MMP-8 detected. 
Immunohistochemical analysis conﬁrmed 
that in the hyperoxic lung, MMP-8 was 
mostly expressed in recruited macrophages, 
which at 48 hours were detectable in the 
perivascular space and subsequently at 60 
hours in the alveoli and interstitium. 
Recently, an unexpected anti-inﬂammatory 
role was evidenced for MMP-8 in the lung 
(Owen et al. 2004, Gueders et al. 2005). 
One possible mechanism is the regulation of 
inﬂammatory cell apoptosis, as demonstrated 
during allergen-induced lung inﬂammation 
by reduced neutrophil apoptosis in MMP-8 
-/- mice (Gueders et al. 2004). During the 
development of hyperoxic lung injury, a large 
number of inﬁltrating inﬂammatory cells 
exist in the rat lung (Barry and Crapo 1985). 
Whether the role of MMP-8 in hyperoxic 
lung injury is anti-inﬂammatory– possibly 
by regulating inﬂammatory cell apoptosis–
remains a subject for future research.
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1)  Higher levels of MMP-8 in association 
with lower levels of TIMP-2 were detected 
in TAF from preterm infants with more 
severe respiratory distress. In addition, 
MMP-8 was higher in TAF during the early 
postnatal period in those preterm infants who 
subsequently developed BPD. 
2)  During the early postnatal period, higher 
pulmonary concentrations of trypsinogen-2 
appeared in preterm infants with more severe 
acute respiratory distress and in those who 
later developed BPD. In addition, the ratio of 
trypsinogen-2 to its speciﬁc inhibitor TATI 
was higher in these infants. 
3)  In the injured preterm lung, trypsin-2 
was expressed in the bronchial and alveolar 
epithelium, where it co-localized with PAR
2
. 
The level of PAR
2 
expression was higher in 
bronchial and alveolar epithelium in preterm 
infants who had died of prolonged RDS 
than in newborn infants without histological 
signs of RDS. In prolonged RDS and BPD, 
PAR
2 
also occurred in myoﬁbroblasts of 
the thickened and ﬁbrotic alveolar walls. 
These ﬁndings suggest that activation 
of PAR
2
 by high levels of trypsin-2 may 
participate in pulmonary inﬂammation and 
ﬁbroproliferation associated with the 
development of BPD.
 
4) In rats exposed to hyperoxia, pulmonary 
levels of trypsin and MMP-8 sharply increased 
after 48 hours of exposure relative to levels 
innormoxia controls. Although alveolar 
epithelium was predominantly negative 
in controls, after 48 hours of hyperoxia it 
showed strong expression of trypsin. Marked 
up-regulation of trypsin and MMP-8 early in 
the course of hyperoxic lung injury suggests 
that they may play a role in the pathogenesis 
of acute lung injury.
CONCLUSIONS
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